

## Clinical Policy: Immune Globulins

Reference Number: CP.PHAR.103

Effective Date: 08.12

Last Review Date: 12.25

Line of Business: Commercial, Medicaid

[Coding Implications](#)
[Revision Log](#)

See [Important Reminder](#) at the end of this policy for important regulatory and legal information.

### Description

The following are immune globulins requiring prior authorization: Alyglo<sup>™</sup>, Asceniv<sup>™</sup>, Bivigam<sup>®</sup>, Cutaquig<sup>®</sup>, Cuvitru<sup>™</sup>, Flebogamma<sup>®</sup> DIF, GamaSTAN<sup>®</sup>, GamaSTAN<sup>®</sup> S/D, Gammagard<sup>®</sup> liquid, Gammagard<sup>®</sup> liquid ERC, Gammagard<sup>®</sup> S/D, Gammaked<sup>™</sup>, Gammaplex<sup>®</sup>, Gamunex<sup>®</sup>-C, Hizentra<sup>®</sup>, HyQvia<sup>®</sup>, Octagam<sup>®</sup>, Panzyga<sup>®</sup>, Privigen<sup>®</sup>, Qivigy<sup>®</sup>, Xembify<sup>®</sup>, and Yimmugo<sup>®</sup>.

### FDA Approved Indication(s)

Brand Name	ROA	PI	ITP	CIDP	KS	MMN	CLL	VPPX	DM
Alyglo	IV	x							
Asceniv	IV	x							
Bivigam	IV	x							
Cutaquig	SC	x							
Cuvitru	SC	x							
Flebogamma DIF	IV	x	x <sup>#</sup>						
GamaSTAN, GamaSTAN S/D	IM							x	
Gammagard liquid	IV, SC	x		x <sup>*</sup>		x <sup>*</sup>			
Gammagard liquid ERC	IV, SC	x							
Gammagard S/D	IV	x	x		x		x		
Gammaked	IV, SC	x	x <sup>*</sup>	x <sup>*</sup>					
Gammaplex	IV	x	x						
Gamunex-C	IV, SC	x	x <sup>*</sup>	x <sup>*</sup>					
Hizentra	SC	x		x					
HyQvia	SC	x		x					
Octagam	IV	x <sup>^</sup>	x <sup>#</sup>						x <sup>#</sup>
Panzyga	IV	x	x	x					
Privigen	IV	x	x	x					
Qivigy	IV	x							
Xembify	SC	x							
Yimmugo	IV	x							

If available as IV and SC, then \* = IV only; If available as 5% and 10%, then: # = 10% only, ^ = 5% only

*ROA = route of administration; CIDP = chronic inflammatory demyelinating polyneuropathy; CLL = B-cell chronic lymphocytic leukemia; DM = dermatomyositis; ITP = idiopathic thrombocytopenic purpura; KS = Kawasaki syndrome; MMN = multifocal motor neuropathy; PI = primary humoral immunodeficiency; VPPX = viral prophylaxis (for hepatitis A, measles, varicella, rubella)*

Limitation(s) of use:

- Safety and efficacy of chronic use of recombinant human hyaluronidase in Hyqiva have not been established in conditions other than PI.
- Privigen maintenance therapy in CIDP has not been studied beyond 6 months.

**Contents:**

**I. Initial Approval Criteria**

- A. Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
- B. CAR T-Cell Related Toxicities
- C. Dermatomyositis/Polymyositis
- D. Fetal/Neonatal Alloimmune Thrombocytopenia
- E. Inflammatory Demyelinating Polyneuropathy (Acute/Guillain-Barre Syndrome or Chronic)
- F. Idiopathic Thrombocytopenia Purpura (Acute or Chronic)
- G. Kawasaki Syndrome Aneurysm Prevention
- H. Kidney Transplant
- I. Multifocal Motor Neuropathy
- J. Multiple Myeloma
- K. Multiple Sclerosis
- L. Myasthenia Gravis/Lambert Eaton Myasthenic Syndrome
- M. Paraneoplastic Neurologic Syndrome
- N. Parvovirus B19 Infection and Anemia
- O. Pediatric Human Immunodeficiency Virus (HIV) Infection Prophylaxis
- P. Pemphigus Vulgaris, Pemphigus Foliaceus, Bullous Pemphigoid, Mucous Membrane Pemphigoid (a.k.a. Cicatricial Pemphigoid, Epidermolysis Bullosa Acquisita)
- Q. Primary Immunodeficiencies
- R. Stiff Person Syndrome
- S. Viral Prophylaxis for Hepatitis A, Measles, Varicella, Rubella Viruses

**II. Continued Therapy**

**III. Diagnoses/Indications for which coverage is NOT authorized**

**IV. Appendices/General Information**

**V. Dosage and Administration**

**VI. Product Availability**

**VII. References**

**Policy/Criteria**

*Provider must submit documentation (such as office chart notes, lab results, or other clinical information) supporting that member has met all approval criteria.*

It is the policy of health plans affiliated with Centene Corporation<sup>®</sup> that immune globulins are **medically necessary** when the following criteria are met:

**I. Initial Approval Criteria**

**A. Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (off-label for SLL) Infection Prophylaxis (must meet all):**

1. Diagnosis of B-cell CLL or small lymphocytic lymphoma (SLL);
2. Prescribed by or in consultation with a hematologist, oncologist, or immunologist;
3. Current (within the last 6 months) hypogammaglobulinemia as evidenced by two separate measurements of immunoglobulin G (IgG) level less than 500 mg/dL;
4. Member has had recurrent serious bacterial infections (e.g., requiring IV antibiotics, hospitalization, or consultation with an infectious disease specialist) within the past 12 months;
5. Member meets one of the following (a, b, c, d, or e):\*
  - a. Request is for the treatment associated with cancer for a State with regulations against step therapy in certain oncology settings (see Appendix G);
  - b. Request is for Gammagard or Gamunex-C unless there is a specific health plan-preferred\* immune globulin product;
  - c. Failure of Gammagard and Gamunex-C (or health plan-preferred\* immune globulin product);
  - d. Member has intolerance or contraindication to Gammagard and Gamunex-C (or health plan-preferred\* immune globulin product), or if Gammagard and Gamunex-C (or health plan-preferred\* immune globulin product) are both unavailable due to shortage, member must use Gammaked<sup>®</sup>, unless contraindicated or clinically significant adverse effects are experienced;
  - e. Gammagard (or health plan-preferred\* immune globulin product), Gamunex-C, and Gammaked, are all unavailable due to shortage, and request is for an immune globulin product other than those listed;
6. Request meets one of the following (a or b) [Note: for adults, calculate dosing based on total body weight (TBW) or ideal body weight (IBW), whichever is less. For obese members, use adjusted body weight (adjBW). (See Appendix F for weight-based dosing calculations.)]:
  - a. Dose does not exceed 400 mg per kg IV every 3 to 4 weeks;
  - b. Dose is supported by practice guidelines or peer-reviewed literature for the relevant off-label use (*prescriber must submit supporting evidence*).

*\*Immune globulin products are generally interchangeable and it is at the health plan's discretion to prefer a clinically appropriate alternative product based on the time of request*

**Approval duration:**

**Medicaid** – 6 months

**Commercial** – 6 months or to the member's renewal date, whichever is longer

**B. CAR T-Cell-Related Toxicities (off-label) (must meet all):**

1. One of the following (a or b)
  - a. Management of G4 cytokine release syndrome (CRS);
  - b. Secondary hypogammaglobulinemia for infection prophylaxis;\*
2. Prescribed by or in consultation with a hematologist, oncologist, or immunologist;

*\*If request is for CAR T-cell therapy in patients with MM, please refer to criteria set J.*

3. For CRS, failure of both high-dose systemic corticosteroids and anti-IL-6 therapy\* (*see Appendix B*), unless clinically adverse effects are experienced or all are contraindicated;
4. For secondary hypogammaglobulinemia for infection prophylaxis, all of the following (a, b, and c):
  - a. Member has received treatment with anti-CD19 CAR T-cell therapy (e.g., axicabtagene ciloleucel, brexucabtagene autoleucel, lisocabtagene maraleucel, tisagenlecleucel, etc);
  - b. Current (within the last 6 months) hypogammaglobulinemia as evidenced by two separate measurements of immunoglobulin G (IgG) level less than 600 mg/dL;
  - c. Member has had recurrent serious bacterial infections (e.g., requiring IV antibiotics, hospitalization, or consultation with an infectious disease specialist) within the past 12 months;
5. Member meets one of the following (a, b, c, d, or e):\*
  - a. Request is for the treatment associated with cancer for a State with regulations against step therapy in certain oncology settings (*see Appendix G*);
  - b. Request is for Gammagard or Gamunex-C unless there is a specific health plan-preferred\* immune globulin product;
  - c. Failure of Gammagard and Gamunex-C (or health plan-preferred\* immune globulin product);
  - d. Member has intolerance or contraindication to Gammagard and Gamunex-C (or health plan-preferred\* immune globulin product), or if Gammagard and Gamunex-C (or health plan-preferred\* immune globulin product) are both unavailable due to shortage, member must use Gammaked, unless contraindicated or clinically significant adverse effects are experienced;
  - e. Gammagard (or health plan-preferred\* immune globulin product), Gamunex-C, and Gammaked, are all unavailable due to shortage, and request is for an immune globulin product other than those listed;

*\*Immune globulin products are generally interchangeable and it is at the health plan's discretion to prefer a clinically appropriate alternative product based on the time of request*
6. Dose is within FDA maximum limit for any FDA-approved indication or is supported by practice guidelines or peer-reviewed literature for the relevant off-label use (*prescriber must submit supporting evidence*)\* [Note: for adults, calculate dosing based on TBW or IBW, whichever is less. For obese members, use adjBW. (*See Appendix F for weight-based dosing calculations.*)].

*\*Prescribed regimen must be FDA-approved or recommended by NCCN.*

**Approval duration:**

**For CRS - 1 month**

**For infection prophylaxis**

- **Medicaid** – 6 months
- **Commercial** – 6 months or to the member's renewal date, whichever is longer

**C. Dermatomyositis, Polymyositis (off-label for polymyositis) (must meet all):**

1. Diagnosis of dermatomyositis (DM) or polymyositis (PM);
2. Prescribed by or in consultation with a dermatologist, rheumatologist, neurologist, or neuromuscular specialist;

3. Failure of a 4-month trial of a systemic corticosteroid (e.g., prednisone) in combination with one of the following immunosuppressive agents, both at up to maximally indicated doses unless clinically significant adverse effects are experienced or all are contraindicated: methotrexate, azathioprine, cyclophosphamide, mycophenolate mofetil, tacrolimus, cyclosporine (*see Appendix D*);
4. For dermatomyositis requests only: Failure of a trial of rituximab\*, unless contraindicated, clinically significant adverse effects are experienced, or the member is diagnosed with juvenile dermatomyositis plus calcinosis;  
*\*Prior authorization may be required for rituximab*
5. Member meets one of the following (a, b, c, d, or e):\*
  - a. For Octagam requests, member has DM;
  - b. Request is for Gammagard or Gamunex-C unless there is a specific health plan-preferred\* immune globulin product;
  - c. Failure of Gammagard and Gamunex-C (or health plan-preferred\* immune globulin product);
  - d. Member has intolerance or contraindication to Gammagard and Gamunex-C (or health plan-preferred\* immune globulin product), or if Gammagard and Gamunex-C (or health plan-preferred\* immune globulin product) are both unavailable due to shortage, member must use Gammaked, unless contraindicated or clinically significant adverse effects are experienced;
  - e. Gammagard (or health plan-preferred\* immune globulin product), Gamunex-C, and Gammaked, are all unavailable due to shortage, and request is for an immune globulin product other than those listed;  
*\*Immune globulin products are generally interchangeable and it is at the health plan's discretion to prefer a clinically appropriate alternative product based on the time of request*
6. Request meets one of the following (a or b) [Note: for adults, calculate dosing based on TBW or IBW, whichever is less. For obese members, use adjBW. (*See Appendix F for weight-based dosing calculations.*)]:
  - a. Dose does not exceed 2 g per kg IV per month;
  - b. Dose is supported by practice guidelines or peer-reviewed literature for the relevant off-label use (*prescriber must submit supporting evidence*).

**Approval duration:**

**Medicaid** – 6 months

**Commercial** – 6 months or to the member's renewal date, whichever is longer

**D. Fetal/Neonatal Alloimmune Thrombocytopenia (off-label)** (must meet all):

1. Diagnosis of fetal/neonatal alloimmune thrombocytopenia (FNAIT);
2. Prescribed by or in consultation with a hematologist, immunologist, perinatologist, or neonatologist;
3. Meets one of the following (a, b, c, or d):
  - a. Previous pregnancy affected by FNAIT;
  - b. Serological confirmation of FNAIT as evidenced by maternal-fetal HPA incompatibility;
  - c. Nadir platelet count < 100 x 10<sup>9</sup>/L at birth or within 7 days after birth of the affected child;
  - d. Fetal intracranial hemorrhage;

4. Member meets one of the following (a, b, c, or d):
  - a. Request is for Gammagard or Gamunex-C unless there is a specific health plan-preferred\* immune globulin product;
  - b. Failure of Gammagard and Gamunex-C (or health plan-preferred\* immune globulin product);
  - c. Member has intolerance or contraindication to Gammagard and Gamunex-C (or health plan-preferred\* immune globulin product), or if Gammagard and Gamunex-C (or health plan-preferred\* immune globulin product) are both unavailable due to shortage, member must use Gammaked, unless contraindicated or clinically significant adverse effects are experienced;
  - d. Gammagard (or health plan-preferred\* immune globulin product), Gamunex-C, and Gammaked, are all unavailable due to shortage, and request is for an immune globulin product other than those listed;  
*\*Immune globulin products are generally interchangeable and it is at the health plan's discretion to prefer a clinically appropriate alternative product based on the time of request*
5. Request meets one of the following (a or b):
  - a. Dose does not exceed 2 g per kg IV per week;
  - b. Dose is supported by practice guidelines or peer-reviewed literature for the relevant off-label use (*prescriber must submit supporting evidence*).

**Approval duration:**

**Medicaid** – 6 months

**Commercial** – 6 months or to the member's renewal date, whichever is longer

**E. Inflammatory Demyelinating Polyneuropathy (Acute/Guillain-Barre Syndrome or Chronic)** (must meet all):

1. Diagnosis of acute inflammatory demyelinating polyneuropathy (AIDP)/Guillain-Barre Syndrome (GBS) or CIDP;
2. Prescribed by or in consultation with a neurologist or neuromuscular specialist;
3. Member meets one of the following (a or b):
  - a. Diagnosis is AIDP/GBS and member meets one of the following (i-vii):
    - i. Inability to stand or walk at least 30 feet without assistance;
    - ii. ICU admission required for aspiration or mechanical ventilation;
    - iii. Miller-Fisher syndrome;
    - iv. Inability to raise head against gravity;
    - v. Severe bulbar palsy (e.g., impaired gag reflex, dysarthria, and/or dysphagia);
    - vi. Bilateral facial weakness;
    - vii. Autonomic dysfunction (e.g., unexplained dysrhythmia, blood pressure fluctuations, significant bowel, or bladder involvement);
  - b. Diagnosis is CIDP and member meets all of the following (i-v):
    - i. Disease is progressive or relapsing for  $\geq 2$  months;
    - ii. Member has either of the following (1 or 2):
      - 1) Both of the following, characterizing typical CIDP (a and b):
        - a) Progressive or relapsing, symmetric proximal and distal muscle weakness of upper and lower limbs and sensory involvement of  $\geq 2$  limbs;
        - b) Absent or reduced tendon reflexes in all limbs;
      - 2) One of the following CIDP variants (a-e):

- a) Distal CIDP;
  - b) Multifocal CIDP;
  - c) Focal CIDP;
  - d) Motor CIDP;
  - e) Sensory CIDP;
- iii. Diagnosis has been confirmed via electrodiagnostic testing;
  - iv. Member does not have any of the following (1-6):
    - 1) *Borrelia burgdorferi* infection (Lyme disease), diphtheria, drug, or toxin exposure probably to have caused the neuropathy;
    - 2) Hereditary demyelinating neuropathy;
    - 3) Prominent sphincter disturbance;
    - 4) Diagnosis of multifocal motor neuropathy;
    - 5) IgM monoclonal gammopathy with high titre antibodies to myelin-associated glycoprotein;
    - 6) Other causes for a demyelinating neuropathy including POEMS syndrome, osteosclerotic myeloma, diabetic and nondiabetic lumbosacral radiculoplexus neuropathy;
  - v. For members who do not have pure motor symptoms, failure of at least one corticosteroid (e.g., prednisone) at up to maximally indicated doses unless contraindicated or clinically significant adverse effects are experienced;
4. Member meets one of the following (a, b, c, or d):\*
- a. Request is for Gammagard or Gamunex-C unless there is a specific health plan-preferred\* immune globulin product;
  - b. Failure of Gammagard and Gamunex-C (or health plan-preferred\* immune globulin product);
  - c. Member has intolerance or contraindication to Gammagard and Gamunex-C (or health plan-preferred\* immune globulin product), or if Gammagard and Gamunex-C (or health plan-preferred\* immune globulin product) are both unavailable due to shortage, member must use Gammaked, unless contraindicated or clinically significant adverse effects are experienced;
  - d. Gammagard (or health plan-preferred\* immune globulin product), Gamunex-C, and Gammaked, are all unavailable due to shortage, and request is for an immune globulin product other than those listed;
- \*Immune globulin products are generally interchangeable and it is at the health plan's discretion to prefer a clinically appropriate alternative product based on the time of request*
5. Request meets one of the following (a, b, or c) [Note: for adults, calculate dosing based on TBW or IBW, whichever is less. For obese members, use adjBW. (See *Appendix F for weight-based dosing calculations*).]:
- a. For AIDP/GB: Dose does not exceed 0.4 g per kg per day IV for 5 days;
  - b. For CIDP (i, ii, or iii):
    - i. Dose does not exceed a loading dose of 2 g per kg IV given in divided doses over 2 to 5 consecutive days, followed by maintenance dose of 1 g per kg IV every 3 weeks;
    - ii. For Hizentra: Dose does not exceed one of the following (1 or 2):
      - 1) 0.2 g per kg body weight SC per week, starting 1 week after last intravenous immune globulin (IVIG) infusion;

- 2) If evidence is submitted demonstrating worsening symptoms on 0.2 g per kg dose, 0.4 g per kg body weight SC per week;
- iii. For HyQvia: Dose does not exceed previous IV dose (*refer to section V for product-specific dosing*);
- c. Dose is supported by practice guidelines or peer-reviewed literature for the relevant off-label use (*prescriber must submit supporting evidence*).

**Approval duration:**

**Medicaid** – 6 months

**Commercial** – 6 months or to the member's renewal date, whichever is longer

**F. Idiopathic Thrombocytopenic Purpura (Acute or Chronic) (must meet all):**

- 1. Diagnosis of acute or chronic ITP;
- 2. Prescribed by or in consultation with a hematologist;
- 3. Member meets one of the following (a or b):
  - a. Failure of one of the following at up to maximally indicated doses, unless clinically significant adverse effects are experienced or both are contraindicated (i or ii):
    - i. Systemic corticosteroids (e.g., prednisone);
    - ii. Rh<sub>o</sub>(D) immune globulin (RhIG)\*;

*\*Prior authorization is required for RhIG*
  - b. Pregnant;
- 4. Member meets one of the following (a – e):
  - a. Current (within the last 30 days) platelet count is < 30,000/ $\mu$ L;
  - b. Actively bleeding;
  - c. High risk of life-threatening hemorrhage;
  - d. Splenectomy is scheduled;
  - e. Pregnant;
- 5. Member meets one of the following (a, b, c, or d):
  - a. Request is for Gammagard or Gamunex-C unless there is a specific health plan-preferred\* immune globulin product;
  - b. Failure of Gammagard and Gamunex-C (or health plan-preferred\* immune globulin product);
  - c. Member has intolerance or contraindication to Gammagard and Gamunex-C (or health plan-preferred\* immune globulin product), or if Gammagard and Gamunex-C (or health plan-preferred\* immune globulin product) are both unavailable due to shortage, member must use Gammaked, unless contraindicated or clinically significant adverse effects are experienced;
  - d. Gammagard (or health plan-preferred\* immune globulin product), Gamunex-C, and Gammaked, are all unavailable due to shortage, and request is for an immune globulin product other than those listed;

*\*Immune globulin products are generally interchangeable and it is at the health plan's discretion to prefer a clinically appropriate alternative product based on the time of request*
- 6. Request meets one of the following (a, b, c, or d) [Note: for adults, calculate dosing based on TBW or IBW, whichever is less. For obese members, use adjBW. (*See Appendix F for weight-based dosing calculations.*)]:
  - a. Dose does not exceed 1 g per kg per day IV for 1 to 2 days;
  - b. Dose does not exceed 400 mg per kg per day IV for up to 5 days;

- c. For Gammagard S/D: Dose does not exceed 1 g per kg for up to 3 total doses QOD;
- d. Dose is supported by practice guidelines or peer-reviewed literatures for the relevant off-label use (*prescriber must submit supporting evidence*).

**Approval duration:**

**Medicaid** – 6 months

**Commercial** – 6 months or to the member’s renewal date, whichever is longer

**G. Kawasaki Syndrome Aneurysm Prevention (must meet all):**

1. Diagnosis of Kawasaki syndrome or incomplete (atypical) Kawasaki disease;
2. Prescribed by or in consultation with a cardiologist, allergist, immunologist, infectious disease specialist, or rheumatologist;
3. Prescribed concurrently with aspirin therapy, unless contraindicated or clinically significant adverse effects are experienced;
4. Member meets one of the following (a, b, c, or d):
  - a. Request is for Gammagard or Gamunex-C unless there is a specific health plan-preferred\* immune globulin product;
  - b. Failure of Gammagard and Gamunex-C (or health plan-preferred\* immune globulin product);
  - c. Member has intolerance or contraindication to Gammagard and Gamunex-C (or health plan-preferred\* immune globulin product), or if Gammagard and Gamunex-C (or health plan-preferred\* immune globulin product) are both unavailable due to shortage, member must use Gammaked, unless contraindicated or clinically significant adverse effects are experienced;
  - d. Gammagard (or health plan-preferred\* immune globulin product), Gamunex-C, and Gammaked, are all unavailable due to shortage, and request is for an immune globulin product other than those listed;

*\*Immune globulin products are generally interchangeable and it is at the health plan’s discretion to prefer a clinically appropriate alternative product based on the time of request*
5. Request meets one of the following (a, b, c, or d):
  - a. Dose does not exceed 1 g per kg IV as a single infusion;
  - b. Dose does not exceed 400 mg per kg IV daily for 4 consecutive days;
  - c. Dose does not exceed 2 g per kg IV as a single infusion;
  - d. Dose is supported by practice guidelines or peer-reviewed literature for the relevant off-label use (*prescriber must submit supporting evidence*).

**Approval duration: One time approval (1 month)**

**H. Kidney Transplant (off-label) (must meet all):**

1. Member meets one of the following (a or b):
  - a. If prescribed prior to kidney transplant, member has high levels of “anti-donor” antibodies (i.e., member is highly sensitized to the tissue of the majority of living or cadaveric donors because of “non-self” human leukocyte antigen (HLA) or ABO incompatibility);
  - b. If prescribed following kidney transplant, used for the treatment of antibody-mediated rejection;
2. Prescribed by or in consultation with a nephrologist, transplant specialist, or hematologist;

3. Member meets one of the following (a, b, c, or d):
  - a. Request is for Gammagard or Gamunex-C unless there is a specific health plan-preferred\* immune globulin product;
  - b. Failure of Gammagard and Gamunex-C (or health plan-preferred\* immune globulin product);
  - c. Member has intolerance or contraindication to Gammagard and Gamunex-C (or health plan-preferred\* immune globulin product), or if Gammagard and Gamunex-C (or health plan-preferred\* immune globulin product) are both unavailable due to shortage, member must use Gammaked, unless contraindicated or clinically significant adverse effects are experienced;
  - d. Gammagard (or health plan-preferred\* immune globulin product), Gamunex-C, and Gammaked, are all unavailable due to shortage, and request is for an immune globulin product other than those listed;  
*\*Immune globulin products are generally interchangeable and it is at the health plan's discretion to prefer a clinically appropriate alternative product based on the time of request*
4. Request meets one of the following (a or b) [Note: for adults, calculate dosing based on TBW or IBW, whichever is less. For obese members, use adjBW. (See Appendix F for weight-based dosing calculations.)]:
  - a. Dose does not exceed 140 g IV per infusion;
  - b. Dose is supported by practice guidelines or peer-reviewed literature for the relevant off-label use (*prescriber must submit supporting evidence*).

**Approval duration:**

**Medicaid** – 6 months

**Commercial** – 6 months or to the member's renewal date, whichever is longer

**I. Multifocal Motor Neuropathy (must meet all):**

1. Diagnosis of MMN;
2. Prescribed by or in consultation with a neurologist or neuromuscular specialist;
3. Member meets one of the following (a, b, c, or d):
  - a. Request is for Gammagard or Gamunex-C unless there is a specific health plan-preferred\* immune globulin product;
  - b. Failure of Gammagard and Gamunex-C (or health plan-preferred\* immune globulin product);
  - c. Member has intolerance or contraindication to Gammagard and Gamunex-C (or health plan-preferred\* immune globulin product), or if Gammagard and Gamunex-C (or health plan-preferred\* immune globulin product) are both unavailable due to shortage, member must use Gammaked, unless contraindicated or clinically significant adverse effects are experienced;
  - d. Gammagard (or health plan-preferred\* immune globulin product), Gamunex-C, and Gammaked, are all unavailable due to shortage, and request is for an immune globulin product other than those listed;  
*\*Immune globulin products are generally interchangeable and it is at the health plan's discretion to prefer a clinically appropriate alternative product based on the time of request*
4. Request meets one of the following (a or b) [Note: for adults, calculate dosing based on TBW or IBW, whichever is less. For obese members, use adjBW. (See Appendix F for weight-based dosing calculations.)]:
  - a. Dose does not exceed 2.4 g per kg IV per month;

- b. Dose is supported by practice guidelines or peer-reviewed literature for the relevant off-label use (*prescriber must submit supporting evidence*).

**Approval duration:**

**Medicaid** – 6 months

**Commercial** – 6 months or to the member's renewal date, whichever is longer

**J. Multiple Myeloma Infection Prophylaxis (off-label) (must meet all):**

1. Diagnosis of multiple myeloma (MM);
2. Prescribed by or in consultation with a hematologist, oncologist, or immunologist;
3. One of the following (a or b):
  - a. If member has received or currently receiving treatment with BCMA-targeted CAR T-cell (e.g., idecabtagene vicleucel or ciltacabtagene autoleucel) or bispecific antibody therapy (e.g., elranatamab-bcmm, or teclistamab-cqyv), current (within the last 6 months) hypogammaglobulinemia as evidenced by two separate measurements of immunoglobulin G (IgG) level less than 400 mg/dL;
  - b. Both of the following (i and ii):
    - i. Current (within the last 6 months) hypogammaglobulinemia as evidenced by two separate measurements of immunoglobulin G (IgG) level less than 400 mg/dL;
    - ii. Member has had recurrent serious bacterial infections (e.g., requiring IV antibiotics, hospitalization, or consultation with an infectious disease specialist) within the past 12 months;
4. Member meets one of the following (a, b, c, d, or e):
  - a. Request is for the treatment associated with cancer for a State with regulations against step therapy in certain oncology settings (see Appendix G);
  - b. Request is for Gammagard or Gamunex-C unless there is a specific health plan-preferred\* immune globulin product;
  - c. Failure of Gammagard and Gamunex-C (or health plan-preferred\* immune globulin product);
  - d. Member has intolerance or contraindication to Gammagard and Gamunex-C (or health plan-preferred\* immune globulin product), or if Gammagard and Gamunex-C (or health plan-preferred\* immune globulin product) are both unavailable due to shortage, member must use Gammaked, unless contraindicated or clinically significant adverse effects are experienced;
  - e. Gammagard (or health plan-preferred\* immune globulin product), Gamunex-C, and Gammaked, are all unavailable due to shortage, and request is for an immune globulin product other than those listed;  
*\*Immune globulin products are generally interchangeable and it is at the health plan's discretion to prefer a clinically appropriate alternative product based on the time of request*
5. Request meets one of the following (a or b) [Note: for adults, calculate dosing based on TBW or IBW, whichever is less. For obese members, use adjBW. (*See Appendix F for weight-based dosing calculations.*)]:
  - a. Dose does not exceed 400 mg per kg IV every 3 weeks;
  - b. Dose is supported by practice guidelines or peer-reviewed literature for the relevant off-label use (*prescriber must submit supporting evidence*).

**Approval duration:**

**Medicaid** – 6 months

**Commercial** – 6 months or to the member’s renewal date, whichever is longer

**K. Multiple Sclerosis (off-label) (must meet all):**

1. Diagnosis of relapsing-remitting multiple sclerosis (MS);
2. Prescribed by or in consultation with a neurologist;
3. Failure of three FDA-approved disease-modifying MS therapies\* (e.g., Avonex, Aubagio<sup>®</sup>, Betaseron<sup>®</sup>, Rebif<sup>®</sup>, Copaxone<sup>®</sup>, Tecfidera<sup>®</sup>, Gilenya<sup>®</sup> (*see Appendix B*)) at up to maximally indicated doses, unless clinically significant side effects are experienced or all are contraindicated;  
*\*Prior authorization is required for MS therapies*
4. Member meets one of the following (a, b, c, or d):
  - a. Request is for Gammagard or Gamunex-C unless there is a specific health plan-preferred\* immune globulin product;
  - b. Failure of Gammagard and Gamunex-C (or health plan-preferred\* immune globulin product);
  - c. Member has intolerance or contraindication to Gammagard and Gamunex-C (or health plan-preferred\* immune globulin product), or if Gammagard and Gamunex-C (or health plan-preferred\* immune globulin product) are both unavailable due to shortage, member must use Gammaked, unless contraindicated or clinically significant adverse effects are experienced;
  - d. Gammagard (or health plan-preferred\* immune globulin product), Gamunex-C, and Gammaked, are all unavailable due to shortage, and request is for an immune globulin product other than those listed;  
*\*Immune globulin products are generally interchangeable and it is at the health plan’s discretion to prefer a clinically appropriate alternative product based on the time of request*
5. Request meets one of the following (a or b) [Note: for adults, calculate dosing based on TBW or IBW, whichever is less. For obese members, use adjBW. (*See Appendix F for weight-based dosing calculations.*)]:
  - a. Dose does not exceed an initial loading dose of 400 mg per kg per day IV for 5 days, followed by maintenance dose of 1 g per kg IV per month;
  - b. Dose is supported by practice guidelines or peer-reviewed literature for the relevant off-label use (*prescriber must submit supporting evidence*).

**Approval duration:**

**Medicaid** – 6 months

**Commercial** – 6 months or to the member’s renewal date, whichever is longer

**L. Myasthenia Gravis (MG)/Lambert Eaton Myasthenic Syndrome (LEMS) (off-label) (must meet all):**

1. Diagnosis of myasthenia gravis (MG) or Lambert Eaton myasthenic syndrome (LEMS);
2. Prescribed by or in consultation with a neurologist or neuromuscular specialist;
3. Member meets one of the following (a, b, or c):
  - a. Acute crisis (e.g., vital capacity less than 1 L/min, inability to walk 100 ft without assistance, intubation, dysphagia with aspiration, mechanical ventilation);
  - b. Thymectomy surgery is scheduled;
  - c. Failure of all of the following at up to maximally indicated doses, unless clinically significant adverse effects are experienced or all are contraindicated (i, ii, and iii):

- i. Amifampridine\* (for LEMS) or a cholinesterase inhibitor (e.g., pyridostigmine; for MG);
  - ii. Systemic corticosteroid (e.g., prednisone);
  - iii. Immunosuppressant (e.g., azathioprine) (*see Appendix B*);  
*\*Prior authorization may be required for amifampridine*
4. Member meets one of the following (a, b, c, or d):
  - a. Request is for Gammagard or Gamunex-C unless there is a specific health plan-preferred\* immune globulin product;
  - b. Failure of Gammagard and Gamunex-C (or health plan-preferred\* immune globulin product);
  - c. Member has intolerance or contraindication to Gammagard and Gamunex-C (or health plan-preferred\* immune globulin product), or if Gammagard and Gamunex-C (or health plan-preferred\* immune globulin product) are both unavailable due to shortage, member must use Gammaked, unless contraindicated or clinically significant adverse effects are experienced;
  - d. Gammagard (or health plan-preferred\* immune globulin product), Gamunex-C, and Gammaked, are all unavailable due to shortage, and request is for an immune globulin product other than those listed;  
*\*Immune globulin products are generally interchangeable and it is at the health plan's discretion to prefer a clinically appropriate alternative product based on the time of request*
5. Request meets one of the following (a or b) [Note: for adults, calculate dosing based on TBW or IBW, whichever is less. For obese members, use adjBW. (*See Appendix F for weight-based dosing calculations.*)]:
  - a. Dose does not exceed 2 g per kg IV divided over 2 to 5 consecutive days per treatment course;
  - b. Dose is supported by practice guidelines or peer-reviewed literature for the relevant off-label use (*prescriber must submit supporting evidence*).

**Approval duration:**

**Medicaid** – 6 months

**Commercial** – 6 months or to the member's renewal date, whichever is longer

**M. Paraneoplastic Neurological Syndrome (off-label) (must meet all):**

1. Diagnosis of one of the following subtypes of paraneoplastic neurological syndrome (a or b):
  - a. Opsoclonus-myoclonus syndrome (OMS);
  - b. Anti-NMDA encephalitis;
2. Prescribed by or in consultation with a neurologist, neuromuscular specialist, or oncologist;
3. For opsoclonus-myoclonus syndrome: Failure of at least one systemic corticosteroid (e.g., prednisone) at up to maximally indicated doses, unless clinically significant adverse effects are experienced or all are contraindicated;
4. Member meets one of the following (a, b, c, or d):
  - a. Request is for Gammagard or Gamunex-C unless there is a specific health plan-preferred\* immune globulin product;
  - b. Failure of Gammagard and Gamunex-C (or health plan-preferred\* immune globulin product);

- c. Member has intolerance or contraindication to Gammagard and Gamunex-C (or health plan-preferred\* immune globulin product), or if Gammagard and Gamunex-C (or health plan-preferred\* immune globulin product) are both unavailable due to shortage, member must use Gammaked, unless contraindicated or clinically significant adverse effects are experienced;
  - d. Gammagard (or health plan-preferred\* immune globulin product), Gamunex-C, and Gammaked, are all unavailable due to shortage, and request is for an immune globulin product other than those listed;  
*\*Immune globulin products are generally interchangeable and it is at the health plan's discretion to prefer a clinically appropriate alternative product based on the time of request*
5. Request meets one of the following (a, b, c, or d) [Note: for adults, calculate dosing based on TBW or IBW, whichever is less. For obese members, use adjBW. (See Appendix F for weight-based dosing calculations.)]:
- a. Dose does not exceed 2 g per kg IV per month;
  - b. Dose does not exceed 0.4 g per kg IV per day;
  - c. Dose does not exceed 200 mg per kg SC per week;
  - d. Dose is supported by practice guidelines or peer-reviewed literature for the relevant off-label use (*prescriber must submit supporting evidence*).

**Approval duration:**

**Medicaid** – 6 months

**Commercial** – 6 months or to the member's renewal date, whichever is longer

**N. Parvovirus B19 Infection and Anemia (off-label) (must meet all):**

- 1. Diagnosis of anemia secondary to chronic parvovirus B19 infection;
- 2. Prescribed by or in consultation with a hematologist, infectious disease specialist, or immunologist;
- 3. Current (within the last 30 days) severe anemia (i.e., Hgb <10 or Hct < 30) due to bone marrow suppression;
- 4. Member meets one of the following (a, b, c, or d):
  - a. Request is for Gammagard or Gamunex-C unless there is a specific health plan-preferred\* immune globulin product;
  - b. Failure of Gammagard and Gamunex-C (or health plan-preferred\* immune globulin product);
  - c. Member has intolerance or contraindication to Gammagard and Gamunex-C (or health plan-preferred\* immune globulin product), or if Gammagard and Gamunex-C (or health plan-preferred\* immune globulin product) are both unavailable due to shortage, member must use Gammaked, unless contraindicated or clinically significant adverse effects are experienced;
  - d. Gammagard (or health plan-preferred\* immune globulin product), Gamunex-C, and Gammaked, are all unavailable due to shortage, and request is for an immune globulin product other than those listed;  
*\*Immune globulin products are generally interchangeable and it is at the health plan's discretion to prefer a clinically appropriate alternative product based on the time of request*
- 5. Request meets one of the following (a or b) [Note: for adults, calculate dosing based on TBW or IBW, whichever is less. For obese members, use adjBW (See Appendix F for weight-based dosing calculations.)]:

- a. Dose does not exceed an initial dose of 2 g per kg per day for up to 5 days, followed by maintenance dose of 400 mg per kg IV every 4 weeks;
- b. Dose is supported by practice guidelines or peer-reviewed literature for the relevant off-label use (*prescriber must submit supporting evidence*).

**Approval duration:**

**Medicaid** – 6 months

**Commercial** – 6 months or to the member's renewal date, whichever is longer

**O. Pediatric Human Immunodeficiency Virus (HIV) Infection Prophylaxis (off-label)**  
(must meet all):

1. Prescribed for prophylaxis of serious bacterial infection in a child who has human immunodeficiency virus (HIV);
2. Prescribed by or in consultation with an HIV or infectious disease specialist;
3. Current (within the last 6 months) hypogammaglobulinemia as evidenced by two separate measurements of serum IgG concentration less than 400 mg/dL;
4. Member meets one of the following (a – e):
  - a. Recurrent serious bacterial infections (defined as two or more infections such as bacteremia, meningitis, or pneumonia in a 12-month period);
  - b. Inadequate antibody response to protein/polysaccharide antigens (e.g., measles, pneumococcal, and/or *Haemophilus influenzae* type b);
  - c. Lives in an area where measles is highly prevalent and has not developed an antibody response after two doses of measles, mumps, and rubella virus live vaccine;
  - d. Exposure to measles (requires a single dose);
  - e. Chronic bronchiectasis that is sub-optimally responsive to antimicrobial and pulmonary therapy;
5. Member meets one of the following (a, b, c, or d):
  - a. Request is for Gammagard or Gamunex-C unless there is a specific health plan-preferred\* immune globulin product;
  - b. Failure of Gammagard and Gamunex-C (or health plan-preferred\* immune globulin product);
  - c. Member has intolerance or contraindication to Gammagard and Gamunex-C (or health plan-preferred\* immune globulin product), or if Gammagard and Gamunex-C (or health plan-preferred\* immune globulin product) are both unavailable due to shortage, member must use Gammaked, unless contraindicated or clinically significant adverse effects are experienced;
  - d. Gammagard (or health plan-preferred\* immune globulin product), Gamunex-C, and Gammaked, are all unavailable due to shortage, and request is for an immune globulin product other than those listed;  
*\*Immune globulin products are generally interchangeable and it is at the health plan's discretion to prefer a clinically appropriate alternative product based on the time of request*
6. Request meets one of the following (a or b):
  - a. Dose does not exceed 400 mg per kg IV every 2 to 4 weeks;
  - b. Dose is supported by practice guidelines or peer-reviewed literature for the relevant off-label use (*prescriber must submit supporting evidence*).

**Approval duration:**

**Medicaid** – 6 months

**Commercial** – 6 months or to the member’s renewal date, whichever is longer

**P. Pemphigus Vulgaris, Pemphigus Foliaceus, Bullous Pemphigoid, Mucous Membrane Pemphigoid (a.k.a. Cicatricial Pemphigoid), Epidermolysis Bullosa Acquisita (off-label) (must meet all):**

1. Diagnosis of one of the following (a, b, c, d, or e):
  - a. Pemphigus vulgaris;
  - b. Pemphigus foliaceus;
  - c. Bullous pemphigoid;
  - d. Mucous membrane pemphigoid (a.k.a. cicatricial pemphigoid);
  - e. Epidermolysis bullosa acquisita;
2. Prescribed by or in consultation with a dermatologist;
3. Failure of at least one corticosteroid (e.g., prednisone) at up to maximally indicated doses unless contraindicated or clinically significant adverse effects are experienced;
4. Failure of at least one immunosuppressive agent (e.g., cyclophosphamide, azathioprine, mycophenolate mofetil) (*see Appendix B*) at up to maximally indicated doses unless contraindicated or clinically significant adverse effects are experienced;
5. Failure of rituximab\* unless contraindicated or clinically significant adverse effects are experienced;  
*\*Prior authorization is required for rituximab*
6. Member meets one of the following (a, b, c, or d):
  - a. Request is for Gammagard or Gamunex-C unless there is a specific health plan-preferred\* immune globulin product;
  - b. Failure of Gammagard and Gamunex-C (or health plan-preferred\* immune globulin product);
  - c. Member has intolerance or contraindication to Gammagard and Gamunex-C (or health plan-preferred\* immune globulin product), or if Gammagard and Gamunex-C (or health plan-preferred\* immune globulin product) are both unavailable due to shortage, member must use Gammaked, unless contraindicated or clinically significant adverse effects are experienced;
  - d. Gammagard (or health plan-preferred\* immune globulin product), Gamunex-C, and Gammaked, are all unavailable due to shortage, and request is for an immune globulin product other than those listed;  
*\*Immune globulin products are generally interchangeable and it is at the health plan’s discretion to prefer a clinically appropriate alternative product based on the time of request*
7. Request meets one of the following (a, b, c, or d) [Note: for adults, calculate dosing based on TBW or IBW, whichever is less. For obese members, use adjBW. (*See Appendix F for weight-based dosing calculations.*)]:
  - a. Dose does not exceed 2 gm per kg IV every 4 weeks;
  - b. Dose does not exceed 400 mg per kg per day IV for 5 days (1 cycle only; may repeat up to three times in a 6-month period);
  - c. Dose does not exceed 300 mg per kg per day IV for 5 days at monthly intervals (for up to 3 cycles);
  - d. Dose is supported by practice guidelines or peer-reviewed literature for the relevant off-label use (*prescriber must submit supporting evidence*).

**Approval duration:**

**Medicaid** – 6 months

**Commercial** – 6 months or to the member’s renewal date, whichever is longer

**Q. Primary Immunodeficiencies** (must meet all):

1. Diagnosis of primary immunodeficiencies (PI), including any of the following (a – h):
  - a. Agammaglobulinemia (e.g., X-linked, congenital);
  - b. Common variable immunodeficiency (CVID);
  - c. Congenital hypogammaglobulinemia;
  - d. Immunodeficiency with near/normal IgM (absent IgG, IgA) (also known as Hyper IgM syndrome);
  - e. Selective immunodeficiency (e.g., selective IgA, IgM, or IgG subclass);
  - f. Severe combined immunodeficiency disorders (SCID) (e.g., X-SCID, jak3, ZAP70, adenosine deaminase (ADA) deficiency, PNP, RAG defects, Ataxia Telangiectasia, Wiskott-Aldrich syndrome, DiGeorge syndrome);
  - g. Subclass deficiency (*see Appendix D*);
  - h. Functional/specific antibody deficiency (*see Appendix D*);
2. Prescribed by or in consultation with an immunologist or hematologist;
3. Member meets one of the following (a or b):
  - a. For functional/specific antibody deficiency, meets all of the following (i, ii, and iii):
    - i. Normal immune globulin levels;
    - ii. Inadequate antibody response to polysaccharide antigens (e.g., pneumococcal);
    - iii. Recurrent serious bacterial infections (e.g., requiring IV antibiotics, hospitalization, or consultation with an infectious disease specialist) within the past 12 months;
  - b. Current (within the last 6 months) total or subclass immune globulin deficiency (below normal for age) as evidenced by two separate measurements of immunoglobulin level (*see Appendix E*) and one of the following (i, ii, iii, or iv):
    - i. For ADA-SCID: failure (defined as experiencing continued recurrent serious bacterial infections) of Revcovi<sup>™</sup>, or hematopoietic stem cell transplant, unless contraindicated or clinically significant adverse effects are experienced;  
*\*Prior authorization is required for Revcovi*
    - ii. SCID (not including ADA-SCID);
    - iii. Recurrent serious bacterial infections (e.g., requiring IV antibiotics, hospitalization, or consultation with an infectious disease specialist) within the past 12 months;
    - iv. Inadequate antibody response to protein/polysaccharide antigens (e.g., tetanus, diphtheria, pneumococcal);
4. Member meets one of the following (a, b, c, or d):
  - a. Request is for Gammagard or Gamunex-C unless there is a specific health plan-preferred\* immune globulin product;
  - b. Failure of Gammagard and Gamunex-C (or health plan-preferred\* immune globulin product);
  - c. Member has intolerance or contraindication to Gammagard and Gamunex-C (or health plan-preferred\* immune globulin product), or if Gammagard and

Gamunex-C (or health plan-preferred\* immune globulin product) are both unavailable due to shortage, member must use Gammaked, unless contraindicated or clinically significant adverse effects are experienced;

- d. Gammagard (or health plan-preferred\* immune globulin product), Gamunex-C, and Gammaked, are all unavailable due to shortage, and request is for an immune globulin product other than those listed;

*\*Immune globulin products are generally interchangeable and it is at the health plan's discretion to prefer a clinically appropriate alternative product based on the time of request*

- 5. Request meets one of the following (a, b, c, or d) [Note: for adults, calculate dosing based on TBW or IBW, whichever is less. For obese members, use adjBW. (See Appendix F for weight-based dosing calculations.)]:

- a. Dose does not exceed 800 mg per kg IV every 3 to 4 weeks;
- b. Dose does not exceed 600 mg per kg SC every 3 to 4 weeks;
- c. Dose does not exceed SC: initial dose of 1.37 x previous initial IV dose given 1 week after last IVIG infusion (*refer to section V. for product-specific dosing frequency*);
- d. Dose is supported by practice guidelines or peer-reviewed literature for the relevant off-label use (*prescriber must submit supporting evidence*).

**Approval duration:**

**Medicaid** – 6 months

**Commercial** – 6 months or to the member's renewal date, whichever is longer

**R. Stiff Person Syndrome (off-label) (must meet all):**

- 1. Diagnosis of stiff person syndrome (also known as Moersch-Woltmann syndrome);
- 2. Prescribed by or in consultation with a neurologist or neuromuscular specialist;
- 3. Failure of a benzodiazepine (e.g., diazepam) or baclofen at up to maximally indicated doses, unless contraindicated or clinically significant adverse effects are experienced;
- 4. Member meets one of the following (a, b, c, or d):

- a. Request is for Gammagard or Gamunex-C unless there is a specific health plan-preferred\* immune globulin product;
- b. Failure of Gammagard and Gamunex-C (or health plan-preferred\* immune globulin product);
- c. Member has intolerance or contraindication to Gammagard and Gamunex-C (or health plan-preferred\* immune globulin product), or if Gammagard and Gamunex-C (or health plan-preferred\* immune globulin product) are both unavailable due to shortage, member must use Gammaked, unless contraindicated or clinically significant adverse effects are experienced;
- d. Gammagard (or health plan-preferred\* immune globulin product), Gamunex-C, and Gammaked, are all unavailable due to shortage, and request is for an immune globulin product other than those listed;

*\*Immune globulin products are generally interchangeable and it is at the health plan's discretion to prefer a clinically appropriate alternative product based on the time of request*

- 5. Request meets one of the following (a or b) [Note: for adults, calculate dosing based on TBW or IBW, whichever is less. For obese members, use adjBW. (See Appendix F for weight-based dosing calculations.)]:

- a. Dose does not exceed 2 g per kg IV divided over 2 to 5 consecutive days per treatment course;

- b. Dose is supported by practice guidelines or peer-reviewed literature for the relevant off-label use (*prescriber must submit supporting evidence*).

**Approval duration:**

**Medicaid** – 6 months

**Commercial** – 6 months or to the member's renewal date, whichever is longer

**S. Viral Prophylaxis for Hepatitis A, Measles, Varicella, Rubella Viruses (must meet all):**

1. Request is for intramuscular formulation;
2. Request is for one of the following indications (a, b, c, or d):
  - a. Hepatitis A post-exposure/high-risk prophylaxis and meets both of the following (i and ii):
    - i. Hepatitis A exposure or at high risk for exposure as evidenced by (1 or 2):
      - 1) Exposure to hepatitis A in the past 2 weeks (e.g., household contact, sexual contact, sharing illicit drugs with someone positive for hepatitis A, regular babysitters/caretakers, food handlers at the same establishment as one who is positive for hepatitis A) AND does not have clinical manifestations of hepatitis A;
      - 2) Traveling to or working in an area endemic for hepatitis A;
    - ii. Meets at least one of the following (1, 2, or 3):
      - 1) Hepatitis A vaccine is locally unavailable;
      - 2) History of severe allergic reaction (anaphylaxis) to the hepatitis A vaccine;
      - 3) If either exposed to the virus or traveling in  $\leq 2$  weeks to an area endemic for hepatitis A, then (a, b, or c):
        - a) Age  $< 1$  year or  $> 40$  years;
        - b) Chronic liver disease or other chronic medical condition;
        - c) Immunocompromised;
  - b. Measles (rubeola) post-exposure prophylaxis and meets all of the following (i, ii, iii, and iv):
    - i. Exposure to measles within the past 6 days;
    - ii. Member has not previously received a measles vaccine;
    - iii. Member has not previously had measles;
    - iv. Meets at least one of the following (1 – 6):
      - 1) Measles vaccine is locally unavailable;
      - 2) History of severe allergic reaction (anaphylaxis) to the measles vaccine;
      - 3) Pregnancy;
      - 4) Immunocompromised;
      - 5) Has been  $> 3$  days since exposure;
      - 6) Age  $< 12$  months;
  - c. Chickenpox (varicella) post-exposure prophylaxis and meets all of the following (i, ii, iii, and iv):
    - i. Exposure to varicella within the past 10 days;
    - ii. Member lacks immunity to varicella;
    - iii. Varicella zoster immune globulin (Varizig) is currently unavailable;
    - iv. Meets any of the following (1 – 5):
      - 1) Varicella vaccine is locally unavailable;

- 2) History of a severe allergic reaction (anaphylaxis) to the varicella vaccine;
- 3) Pregnancy;
- 4) Immunocompromised;
- 5) Newborn of mother who had varicella from 5 days before to 2 days after delivery;
- d. Rubella post-exposure prophylaxis (i and ii):
  - i. Recent exposure to rubella;
  - ii. Member is pregnant;
3. Request meets one of the following (a – e) [Note: for adults, calculate dosing based on TBW or IBW, whichever is less. For obese members, use adjBW. (*See Appendix F for weight-based dosing calculations.*)]:
  - a. Hepatitis A (i, ii, or iii): Dose does not exceed:
    - i. 0.1 mL/kg IM once;
    - ii. For anticipated exposure up to 2 months: 0.2 mL/kg IM once;
    - iii. For anticipated exposure 2 months or longer: 0.2 mL/kg IM every 2 months;
  - b. Measles: Dose does not exceed 15 mL IM once;
  - c. Varicella: Dose does not exceed 1.2 mL/kg IM once;
  - d. Rubella: Dose does not exceed 0.55 mL/kg IM once;
  - e. Dose is supported by practice guidelines or peer-reviewed literature for the relevant off-label use (*prescriber must submit supporting evidence*).

**Approval duration:**

**Hepatitis A:** Duration of request or 6 months, whichever is less

**All other indications:** One time approval (1 month)

**T. Other diagnoses/indications** (must meet 1 and 2):

1. One of the following (a, b, c, d, or e):
  - a. Request is for the treatment associated with cancer for a State with regulations against step therapy in certain oncology settings (see Appendix G);
  - b. Request is for Gammagard or Gamunex-C unless there is a specific health plan-preferred\* immune globulin product;
  - c. Failure of Gammagard and Gamunex-C (or health plan-preferred\* immune globulin product);
  - d. Member has intolerance or contraindication to Gammagard and Gamunex-C (or health plan-preferred\* immune globulin product), or if Gammagard and Gamunex-C (or health plan-preferred\* immune globulin product) are both unavailable due to shortage, member must use Gammaked, unless contraindicated or clinically significant adverse effects are experienced;
  - e. Gammagard (or health plan-preferred\* immune globulin product), Gamunex-C, and Gammaked, are all unavailable due to shortage, and request is for an immune globulin product other than those listed;
- \*Immune globulin products are generally interchangeable and it is at the health plan's discretion to prefer a clinically appropriate alternative product based on the time of request
2. One of the following (a or b)
  - a. If this drug has recently (within the last 6 months) undergone a label change (e.g., newly approved indication, age expansion, new dosing regimen) that is not yet reflected in this policy, refer to one of the following policies (i or ii):

- i. For drugs on the formulary (commercial, health insurance marketplace) or PDL (Medicaid), the no coverage criteria policy for the relevant line of business: CP.CPA.190 for commercial and CP.PMN.255 for Medicaid; or
- ii. For drugs NOT on the formulary (commercial, health insurance marketplace) or PDL (Medicaid), the non-formulary policy for the relevant line of business: CP.CPA.190 for commercial and CP.PMN.16 for Medicaid; or
- b. If the requested use (e.g., diagnosis, age, dosing regimen) is NOT specifically listed under section III (Diagnoses/Indications for which coverage is NOT authorized) AND criterion 2a above does not apply, refer to the off-label use policy for the relevant line of business: CP.CPA.09 for commercial and CP.PMN.53 for Medicaid.

## II. Continued Therapy

### A. Kawasaki Syndrome/Incomplete (Atypical) Kawasaki Disease, Viral Prophylaxis (Hep A, Measles, Varicella, Rubella)

1. Re-authorization is not permitted. Members must meet the initial approval criteria.  
**Approval duration: Not applicable**

### B. CAR T-Cell Related Toxicities

1. For CRS, re-authorization is not permitted.
2. For secondary hypogammaglobulinemia for infection prophylaxis, please use criteria set Section II.C. – All Other Indications.

**Approval duration: Not applicable**

### C. All Other Indications in Section I (must meet all):

1. Member meets one of the following (a or b):
  - a. Currently receiving medication via Centene benefit or member has previously met initial approval criteria;
  - b. Member is currently receiving medication and is enrolled in a state and product with continuity of care regulations (*refer to state specific addendums for CC.PHARM.03A and CC.PHARM.03B*);
2. Member is responding positively to therapy (*see Appendix D for examples*);
3. For members currently receiving Gammagard or Gamunex-C (or health plan-preferred\* immune globulin product), member continues to use Gammagard or Gamunex-C (or health plan-preferred\* immune globulin product), unless medical justification supports necessity for immune globulin product switch (e.g., adverse reactions, product ineffectiveness);  
*\* Immune globulin products are generally interchangeable and it is at the health plan's discretion to prefer a clinically appropriate alternative based on the time of request*
4. If request is for a dose increase due to inadequate response to previous dose, request meets one of the following (a or b) [Note: for adults, calculate dosing based on TBW or IBW, whichever is less, and for obese members use adjBW, unless the newly calculated dose is lower than the currently administered dose. (*See Appendix F for weight-based dosing calculations*)]:
  - a. Dose titration or conversion is appropriate per package insert labeling;
  - b. New dose is supported by practice guidelines or peer-reviewed literature for the relevant off-label use (*prescriber must submit supporting evidence*);

5. For adults with diagnoses other than primary immunodeficiency or cancer-related infection prophylaxis: the requested dose is calculated based on TBW or IBW, whichever is less, and for obese members adjBW is used for dose calculation, unless documentation supports the inability to adjust dosing in this manner (*See Appendix F for weight-based dosing calculations*).

**Approval duration:**

**Medicaid** – 6 months

**Commercial** – 6 months or to the member’s renewal date, whichever is longer

**D. Other diagnoses/indications (must meet 1 and 2):**

1. For members currently receiving Gammagard or Gamunex-C (or health plan-preferred\* immune globulin product), member continues to use Gammagard or Gamunex-C (or health plan-preferred\* immune globulin product), unless medical justification supports necessity for immune globulin product switch (e.g., adverse reactions, product ineffectiveness);  
*\* Immune globulin products are generally interchangeable and it is at the health plan’s discretion to prefer a clinically appropriate alternative based on the time of request*
2. One of the following (a or b):
  - a. If this drug has recently (within the last 6 months) undergone a label change (e.g., newly approved indication, age expansion, new dosing regimen) that is not yet reflected in this policy, refer to one of the following policies (I or ii):
    - i. For drugs on the formulary (commercial, health insurance marketplace) or PDL (Medicaid), the no coverage criteria policy for the relevant line of business: CP.CPA.190 for commercial and CP.PMN.255 for Medicaid; or
    - ii. For drugs NOT on the formulary (commercial, health insurance marketplace) or PDL (Medicaid), the non-formulary policy for the relevant line of business: CP.CPA.190 for commercial and CP.PMN.16 for Medicaid; or
  - b. If the requested use (e.g., diagnosis, age, dosing regimen) is NOT specifically listed under section III (Diagnoses/Indications for which coverage is NOT authorized) AND criterion 2a above does not apply, refer to the off-label use policy for the relevant line of business: CP.CPA.09 for commercial and CP.PMN.53 for Medicaid.

**III. Diagnoses/Indications for which coverage is NOT authorized:**

- A. Non-FDA approved indications, which are not addressed in this policy, unless there is sufficient documentation of efficacy and safety according to the off label use policies – CP.CPA.09 for commercial and CP.PMN.53 for Medicaid, or evidence of coverage documents;
- B. The following are conditions for which treatment with immune globulins is considered not medically necessary:
  1. Acquired factor VIII inhibitors;
  2. Adrenoleukodystrophy;
  3. Alzheimer’s disease;
  4. Amyotrophic lateral sclerosis;
  5. Angioedema;
  6. Antiphospholipid syndrome (APS) [note: coverage exclusion of catastrophic antiphospholipid syndrome (CAPS) does not apply];

7. Aplastic anemia;
8. Asthma;
9. Autism;
10. Autoimmune chronic urticaria;
11. Behçet's syndrome;
12. Cardiomyopathy, acute;
13. Chronic fatigue syndrome;
14. Chronic sinusitis;
15. Complex pain regional syndrome (CPRS);
16. Congenital heart block;
17. Critical illness myopathy (necrotizing myopathy) (ICD10: G7281);
18. Cystic fibrosis;
19. Diabetes mellitus;
20. Diamond-Blackfan anemia;
21. Dysautonomia, acute idiopathic;
22. Eczema;
23. Encephalopathy, acute;
24. Endotoxemia;
25. Epilepsy;
26. Goodpasture's syndrome;
27. Hemolytic transfusion reaction;
28. Hemolytic-uremic syndrome;
29. Hemophagocytic syndrome;
30. Idiopathic lumbosacral flexopathy;
31. Idiopathic progressive neuropathy (ICD10: G603);
32. Immune-mediated neutropenia;
33. Inclusion body myositis;
34. Infection prevention and control in newborns;
35. Intractable seizures;
36. Iridocyclitis, unspecified (ICD10: H209);
37. Lower motor neuron syndrome;
38. Multiple sclerosis – primary progressive or secondary types;
39. Myalgia, myositis, unspecified;
40. Myelopathy, HTLV-I associated;
41. Nephropathy, membranous;
42. Nephrotic syndrome;
43. Non-immune thrombocytopenia;
44. Ophthalmopathy, euthyroid;
45. Oral use;
46. Orbital myositis, bilateral (ICD10: H05123);
47. Other diseases of capillaries [Clarkson disease (systemic capillary leak syndrome)] (ICD10: I788);
48. Otitis media, recurrent;
49. Paraneoplastic cerebellar degeneration;
50. Paraproteinemic neuropathy;

51. Pediatric autoimmune neuropsychiatric disorders associated with streptococcal infection (PANDAS) [note: coverage exclusion of PANDAS does not apply to requests from Arkansas, California, Illinois, Indiana, New Hampshire, and Oregon; For Arkansas, requests for PANS/PANDAS should be evaluated using the state-specific AR.CP.PHAR.103 policy];
52. POEMS syndrome (see General Information – Section IV for definition);
53. Polyarteritis nodosa;
54. Progressive lumbosacral plexopathy;
55. Radiculoneuritis, Lyme;
56. Recurrent otitis media;
57. Recurrent spontaneous pregnancy loss;
58. Refractoriness to platelet transfusion;
59. Reiter's syndrome;
60. Renal failure, acute;
61. Rheumatoid arthritis (adult and juvenile);
62. Scleroderma;
63. Secondary immunodeficiencies induced by biologic therapies, maintenance or chronic treatment;
64. Sensory neuropathy;
65. Systemic lupus erythematosus;
66. Thrombocytopenia (non-immune);
67. Vasculitis associated with other connective tissue diseases;
68. Vogt-Koyanagi-Harada syndrome.

#### **IV. Appendices/General Information**

##### *Appendix A: Abbreviation/Acronym Key*

ACTH: adrenocorticotrophic hormone  
ADA: adenosine deaminase  
adjBW: adjusted body weight  
AIDP: acute inflammatory demyelinating polyneuropathy  
CIDP: chronic inflammatory demyelinating polyneuropathy  
CLL: chronic lymphocytic leukemia  
CRS: cytokine release syndrome  
CVID: common variable immunodeficiency  
DIF: dual inactivation plus nanofiltration  
DM: dermatomyositis  
FNAIT: fetal/neonatal alloimmune thrombocytopenia  
FDA: Food and Drug Administration  
GBS: Guillain Barre Syndrome  
HIV: human immunodeficiency virus  
HLA: human leukocyte antigen  
HPA: human platelet antigen

IBW: ideal body weight  
IG: immune globulin  
IgA: immune globulin A  
IgG: immune globulin G  
IgM: immune globulin M  
IGIV: immune globulin intravenous  
IMIG: intramuscular immune globulin  
ITP: immune thrombocytopenic purpura  
IVIG: intravenous immune globulin  
LEMS: Lambert Eaton myasthenic syndrome  
MG: myasthenia gravis  
MM: multiple myeloma  
MMN: multifocal motor neuropathy  
NAIT: neonatal alloimmune thrombocytopenia  
NF: nanofiltered  
NMDA: N-methyl D-aspartate  
OMS: opsoclonus-myoclonus syndrome

PI: primary [humoral]  
immunodeficiency  
PM: polymyositis  
POEMS: polyneuropathy,  
organomegaly, endocrinopathy,  
monoclonal protein, skin changes  
RhIG: Rh<sub>o</sub>(D) immune globulin  
SC: subcutaneous

SCID: severe combined  
immunodeficiency disorders  
SCIG: subcutaneous immune globulin  
S/D: solvent/detergent treated  
SLL: small lymphocytic lymphoma  
TBW: total body weight  
VZIG: varicella zoster immune globulin

*Appendix B: Therapeutic Alternatives*

*This table provides a listing of preferred alternative therapy recommended in the approval criteria. The drugs listed here may not be a formulary agent for all relevant lines of business and may require prior authorization.*

Drug Name	Dosing Regimen	Dose Limit/ Maximum Dose
baclofen (Lioresal <sup>®</sup> )	<b>Stiff Person Syndrome*</b> 20 mg PO BID or TID, or 50 to 1,600 mcg/day intrathecally	PO: 80 mg/day IT: 1600 mcg/day
diazepam (Valium <sup>®</sup> )	<b>Stiff Person Syndrome*</b> 20 to 80 mg/day PO (given in divided doses)	Daily doses needed to control the disease can be as high as 100 to 200 mg/day in some patients
Firdapse <sup>®</sup> (amifampridine)	<b>LEMS</b> <i>Adults:</i> 15 mg to 30 mg PO in 3 to 4 divided doses daily. Dose can be increased by 5 mg daily every 3 to 4 days.	80 mg/day (20 mg/dose)
Ruzurgi <sup>®</sup> (amifampridine)	<b>LEMS</b> <i>Pediatric (age 6 to &lt;17 years) and weight ≥ 45 kg:</i> 15 to 30 mg PO in 2 to 3 divided doses. Dose can be increased by 5 mg to 10 mg increments daily, divided in up to 5 doses per day.  <i>Pediatric (age 6 to &lt;17 years) and weight &lt; 45 kg:</i> 7.5 mg to 15 mg PO in 2 to 3 divided doses. Dose can be increased by 2.5 mg to 5 mg increments daily, divided in up to 5 doses per day.	100 mg/day (30 mg/dose) for weight ≥ 45 kg; 50 mg/day (15 mg/dose) for weight < 45 kg)
pyridostigmine (Mestinon <sup>®</sup> ); Mestinon <sup>®</sup> Timespan (pyridostigmine extended release)	<b>MG</b> <u>Immediate Release (IR) tablets and syrup</u> <i>Adults:</i> 60 to 1,500 mg PO daily in divided doses (avg 600 mg PO daily) <i>Pediatrics*:</i> 1 mg/kg PO Q4 to 6 hrs <u>Extended Release</u>	IR: 1,500 mg/day (adults) or 7 mg/kg/day (pediatrics) ER: 1,080 mg/day

Drug Name	Dosing Regimen	Dose Limit/ Maximum Dose
	180 to 540 mg PO QD or BID	
Revcovi <sup>™</sup> (elapegamase-lvlr)	<b>ADA-SCID</b> Adagen-naïve: 0.2 mg/kg twice a week IM Transitioning from Adagen: 0.2 mg/kg weekly IM	0.4 mg/kg/week
Rhophylac, WinRho SDF (Rh <sub>o</sub> (D) immune globulin)	<b>ITP in non-splenectomized, Rh<sub>o</sub>(D) antigen positive patients</b> <u>Initial:</u> 50 mcg/kg IV <u>Maintenance Therapy:</u> 25 to 60 mcg/kg IV	75 mcg/kg*
Rituxan <sup>®</sup> (rituximab)	<b>Pemphigus Vulgaris</b> <u>Initial:</u> Two-1000 mg IV infusions separated by 2 weeks in combination with a tapering course of glucocorticoids <u>Maintenance Therapy:</u> 500 mg IV at month 12 and every 6 months thereafter  <b>DM/PM*</b> 1,000 mg/m <sup>2</sup> IV weekly x 2 weeks	500 mg/6 months
<b><i>Immunosuppressive agents</i></b>		
azathioprine (Imuran <sup>®</sup> )	<b>DM/PM*, MG*</b> 2 mg/kg PO QD or 50 mg/day PO up to 2 to 3 mg/kg/day  <b>Pemphigus vulgaris and associated conditions*</b> 2 to 3 mg/kg/day PO	3 mg/kg/day
cyclophosphamide (Cytoxan <sup>®</sup> )	<b>DM/PM*</b> 1 to 3 mg/kg/day PO QD or 500 mg IV every 2 weeks for 6 doses  <b>Pemphigus vulgaris and associated conditions*</b> 50 to 75 mg/day PO or pulsed regimen of 500 mg IV on day, and then every 4 weeks thereafter in combination with oral cyclophosphamide and dexamethasone	Not applicable
cyclosporine (Gengraf <sup>®</sup> , Neoral <sup>®</sup> , Sandimmune <sup>®</sup> )	<b>DM/PMs*, MG*</b> 5 to 10 mg/kg/day PO	Not applicable
methotrexate (Rheumatrex <sup>®</sup> )	<b>DM/PMs*</b> 10 to 25 mg/week PO/IV	50 mg/week

Drug Name	Dosing Regimen	Dose Limit/ Maximum Dose
mycophenolate mofetil (Cellcept <sup>®</sup> )	<b>DM/PM*</b> 250 to 500 mg PO BID, increasing to a target dose of 1,500-3,000 mg/day  <b>MG*</b> 1 g PO BID  <b>Pemphigus vulgaris and associated conditions*</b> 35 to 45 mg/kg/day PO or 1 g PO BID	DM/PM: 3 g/day  PV, etc: 2 g/day
tacrolimus (Prograf <sup>®</sup> )	<b>DM/PM*</b> 0.075mg/kg/day PO BID OR begin at 1 mg PO BID, increase to reach trough of 5-10 ng/ml  <b>MG*</b> 3 mg PO QD	Not applicable
Systemic corticosteroids (e.g., prednisone, prednisolone, methylprednisolone)	An equivalent dose of prednisone 1 mg/kg/day (with or without tapering)	2 mg/kg/day
<b><i>Disease-modifying therapies for relapsing remitting MS</i></b>		
Aubagio <sup>®</sup> (teriflunomide)	7 or 14 mg PO QD	14 mg/day
Avonex <sup>®</sup> , Rebif <sup>®</sup> (interferon beta-1a)	<i>Avonex</i> : 30 mcg IM Q week <i>Rebif</i> : 22 mcg or 44 mcg SC TIW	<i>Avonex</i> : 30 mcg/week <i>Rebif</i> : 44 mcg TIW
Betaseron <sup>®</sup> , Extavia <sup>®</sup> (interferonbeta-1b)	250 mcg SC QOD	250 mg QOD
glatiramer acetate (Copaxone <sup>®</sup> , Glatopa <sup>®</sup> )	<i>Copaxone</i> : 20 mg SC QD or 40 mg SC TIW <i>Glatopa</i> : 20 mg SC QD	<i>Copaxone</i> : 20 mg/day or 40 mg TIW <i>Glatopa</i> : 20 mg/day
Gilenya <sup>®</sup> (fingolimod)	0.5 mg PO QD	0.5 mg/day
Lemtrada <sup>®</sup> (alemtuzumab)	IV infusion for 2 treatment courses: <ul style="list-style-type: none"> <li>First course: 12 mg/day on 5 consecutive days</li> </ul>	See regimen

Drug Name	Dosing Regimen	Dose Limit/ Maximum Dose
	<ul style="list-style-type: none"> <li>Second course: 12 mg/day on 3 consecutive days 12 months after first course</li> </ul>	
Novantrone <sup>®</sup> (mitoxantrone)	12 mg/m <sup>2</sup> given as a short (approximately 5 to 15 minutes) IV every 3 months	Cumulative lifetime dose of $\geq 140$ mg/m <sup>2</sup>
Ocrevus <sup>®</sup> (28ntravenous)	Initial: 300 mg IV, then 300 mg IV 2 weeks later Maintenance: 600 mg IV every 6 months	600 mg/6 months
Plegridy <sup>®</sup> (peginterferon beta-1a)	125 mcg SC Q2 weeks	125 mcg/2 weeks
Tecfidera <sup>®</sup> (dimethyl fumarate)	120 mg PO BID for 7 days, followed by 240 mg PO BID	480 mg/day
Tysabri <sup>®</sup> (natalizumab)	300 mg IV every 4 weeks	300 mg/4 weeks
Zinbryta <sup>®</sup> (daclizumab)	150 mg SC once monthly	150 mg/month
<b><i>CAR T-Cell Related Toxicities</i></b>		
Actemra <sup>®</sup> (tocilizumab)	8 mg /kg IV over 1 hour (not to exceed 800 mg/dose).  Repeat in 8 hours if no improvement; no more than 3 doses in 24 hours with a maximum of 4 doses total.	800 mg per dose (max 4 doses total)
dexamethasone (Decadron <sup>®</sup> , Dexasone <sup>®</sup> )	10 mg IV every 6 hours	Varies
methylprednisolone (Solumedrol <sup>®</sup> , Medrol <sup>®</sup> )	1000 mg IV every 12-24 hours	Varies

Therapeutic alternatives are listed as Brand name<sup>®</sup> (generic) when the drug is available by brand name only and generic (Brand name<sup>®</sup>) when the drug is available by both brand and generic.

\*Off-label

#### *Appendix C: Contraindications/Boxed Warnings*

- Contraindication(s):
  - History of anaphylactic or severe systemic reactions to human immune globulin
  - IgA-deficient patients with antibodies against IgA and a history of hypersensitivity
- Boxed warning(s): thrombosis, renal dysfunction, and acute renal failure

#### *Appendix D: General Information*

- **CLL/SLL:**
  - These patients have a pattern of infection caused by encapsulated bacteria (*Haemophilus influenzae*, pneumococci, streptococci) which tends to be chronic and/or recurrent and does not demonstrate improvement with an adequate course of PO antibiotics and/or prophylactic antibiotics. Recurrent infections may include sinus infections, otitis media, bronchiectasis, and pyogenic pneumonias.
- **CAR T-Cell Related Toxicities:**
  - Infections following CAR T-cell therapy are common. NCCN recommends IVIG replacement for certain patients treated with anti-CD19 CAR T-cell therapy who experience serious or recurrent infections concurrently with hypogammaglobulinemia. IVIG should be continued until serum IgG levels normalize and infections are resolved.
- **DM or PM:**
  - Per the 2020 American Academy of Dermatology treatment guidelines for DM, in cases where a combination of systemic corticosteroids and an oral immunosuppressant fail, rituximab is the appropriate next step in therapy. In individuals with vasculopathic or calcinotic lesions, adults with anti-MDA5 positivity, or children with NXP-2 positivity, rituximab plus systemic corticosteroids can be considered first-line treatment. Additionally, patients with juvenile dermatomyositis and calcinosis should be preferentially treated with IVIG because it has the best data supporting its use for calcinosis specifically.
  - IVIG may be medically necessary after less than 4 months trial of prednisone or prednisone combination therapies if the patient has profound, rapidly progressive and/or potentially life-threatening muscular weakness (e.g., life-threatening aggressive disease with involvement of respiratory musculature, possibly requiring hospitalization, elective intubation and mechanical ventilatory support) and is refractory to or intolerant of previous therapy.
  - Failure or clinically significant adverse effects to continual high dose steroids in combination with other immunosuppressive agents is defined as the patient being unresponsive or poorly responsive to therapy (persistently elevated serum creatine kinase (CK) levels and/or lack of improvement on muscle strength improvement scales) or intolerant of therapy (i.e., steroid myopathy or severe osteoporosis).
  - Inclusion body myositis (IBM) is classified as one of the idiopathic inflammatory myopathies. However, despite some histologic similarities, the clinical manifestations, treatment, and prognosis are different from DM and PM. IBM is relatively resistant to standard immunosuppressive therapy. In two clinical studies, IVIG was unable demonstrate objective improvement in the treatment of IBM.
- **ITP:**
  - Definitions of acute vs. chronic ITP:
    - Per an International Working Group consensus panel of ITP experts, ITP is defined as newly diagnosed (diagnosis to 3 months), persistent (3 to 12 months from diagnosis), or chronic (lasting for more than 12 months). Although not formally validated, these definitions are supported and used by the American Society of Hematology (ASH).
    - In clinical trials evaluating the efficacy and safety of IVIG in ITP, acute ITP was defined as condition duration of up to 6 months while chronic ITP was defined as condition duration of greater than 12 months.

- Response to treatment was defined by the following:
  - Per the 2019 ASH guidelines:
    - Early response is as a platelet count  $\geq 30,000/\mu\text{L}$  and at least doubling baseline at 1 week
    - Initial response is defined as a platelet count  $\geq 30,000/\mu\text{L}$  and at least doubling baseline at 1 month
    - Durable response is defined as a platelet count  $\geq 30,000/\mu\text{L}$  and at least doubling baseline at 6 months
  - Per the 2009 International Working Group consensus panel of ITP excerpts:
    - Platelet counts should be confirmed on at least 2 separate occasions (at least 7 days apart when used to define complete response [CR] or response [R]) or 1 day apart when used to define no response [NR] or loss of response
    - CR: platelet  $\geq 100,000/\mu\text{L}$  and absence of bleeding
    - R: platelet count  $\geq 30,000/\mu\text{L}$  and at least 2-fold increase the baseline count and absence of bleeding
    - NR: platelet  $< 30,000/\mu\text{L}$  or less than 2-fold increase of baseline platelet count or bleeding
    - Loss of CR or R: platelet count below  $100,000/\mu\text{L}$  or bleeding (from CR) or below  $30,000/\mu\text{L}$  or less than 2-fold increase of baseline platelet count or bleeding (from R)
- There have been reports of fatal intravascular hemolysis with Rho(D) immune globulin and specific monitoring is required. This therapy is not necessarily recommended over IVIG but can be used instead in patients who are Rh positive, have a negative direct antiglobulin test (DAT), and have not had a splenectomy.
- For acute ITP, a single dose of IVIG is used as first line treatment. For adults, a second dose may be given if necessary.
- AIDP or GBS:
  - GBS subtypes include the following: acute inflammatory demyelinating polyneuropathy (AIDP), acute motor axonal neuropathy (AMAN), acute motor-sensory axonal neuropathy (AMSAN), and Miller Fisher syndrome (MFS).
  - Miller Fisher syndrome is a rare, acute polyneuropathy characterized by ataxia (abnormal muscle coordination), ophthalmoplegia (paralysis of the eye muscles), and areflexia (absence of the reflexes).
  - Elevated CSF protein, with a normal CSF white blood cell count, is often present; fifty to 66 percent the first week of symptoms and  $\geq 75$  percent the third week.
  - GBS and AIDP typically progresses over 2 weeks, and the majority of patients achieve nadir of the disease by four weeks.
  - Initiation of IVIG within 2 weeks of symptom onset appears to be as effective as plasma exchange (PE).
  - The combination of IVIG and plasmapheresis used together is not better than either treatment used alone.
  - The combination of IVIG and IV methylprednisolone was not more effective than IVIG alone.
  - Immunoabsorption is an alternative technique to PE that removes immunoglobulins. There is insufficient evidence to recommend the use of immunoabsorption for GBS.
  - CSF filtration is as effective as PE for treatment of GBS.

- Pulmonary function risk factors include one or more of the following:
  - Forced vital capacity < 20 mL/kg
  - Maximal inspiratory pressure < 30 cm H<sub>2</sub>O
  - Maximal inspiratory pressure < 40 cm H<sub>2</sub>O
  - 30% reduction in vital capacity from baseline
- CIDP:
  - CIDP is divided into typical CIDP and CIDP variants. CIDP variants are now well characterized entities, each presenting with a specific clinical and electrodiagnostic phenotype. For diagnostic criteria specific to each of the CIDP variants, refer to the 2021 EAN/PNS CIDP guideline.
  - IVIG, corticosteroids, and plasma exchange are recommended treatments for patients with disabling symptoms. Plasma exchange is similarly effective to IVIG and corticosteroids but typically reserved for treatment-refractory patients; it may be less tolerated and more difficult to administer. Patient-specific factors may determine the appropriate choice of therapy.
- Kawasaki Disease:
  - The efficacy of IVIG administered in the acute phase of Kawasaki disease in reducing the prevalence of coronary artery abnormalities is well-established. The mechanism of action of IVIG in treating Kawasaki disease is unknown; however IVIG appears to have a generalized anti-inflammatory effect.
  - For patients with persistent or recurrent fever after initial IVIG infusion, IVIG retreatment may be useful. Failure to respond usually is defined as persistent or recrudescence fever  $\geq 36$  hours after completion of the initial IVIG infusion. Most experts recommend retreatment with IVIG, 2 g/kg. The putative dose-response effect of IVIG forms the theoretical basis for this approach.
- Kidney Transplant:
  - Centene considers the combination of IVIG and Rituxan (rituximab) for desensitization prior to renal transplantation, investigational at this time. Larger, prospective, randomized controlled trials are needed to evaluate the long-term efficacy and safety of this treatment and to compare this protocol with the current treatment of IVIG alone.
  - In a retrospective analysis of 50 kidney transplant patients at Johns Hopkins Hospital, all patients were live donor HLA incompatible recipients. Desensitization included plasmapheresis with low dose IVIG, mycophenolate and tacrolimus, and intraoperative induction therapy with anti-IL2 receptor antibodies. Twenty five of the higher risk patients also received rituximab (375 mg/m<sup>2</sup>) the day prior to transplant. There was no significant difference in the incidence of acute rejection within the first 3 months of transplant between the two groups. Further randomized, controlled trials are still needed.
- MMN:
  - Although not required for diagnosis, the presence of a high titer ( $>1:1000$ ) of serum Immunoglobulin M (IgM) antibody directed against ganglioside-monodialic acid (IgM Anti-GM1 antibodies) provides independent support for MMN ( $> 80\%$  of patients).
  - Although no reports exist of controlled trials of immunosuppressive drugs in patients with multifocal motor neuropathy, there are a series of anecdotal reports of patients who transiently responded to oral or pulsed doses of cyclophosphamide, however, this

treatment was associated with significant side effects, related in part to the cumulative dose of cyclophosphamide.

- MM:
  - These patients have a pattern of infection caused by encapsulated bacteria (*Haemophilus influenzae*, pneumococci, streptococci) which tends to be chronic and/or recurrent and does not demonstrate improvement with an adequate course of PO antibiotics and/or prophylactic antibiotics. Recurrent infections may include sinus infections, otitis media, bronchiectasis, and pyogenic pneumonias.
- MS:
  - The clinical course of MS usually falls within one of the following categories, with the potential for progression from one pattern to a more serious one:
    - Relapsing-remitting MS: This form of MS is characterized by clearly defined acute attacks with full recovery or with some remaining neurological signs/symptoms and residual deficit upon recovery. The periods between disease relapses are characterized by a lack of disease progression.
    - Secondary progressive MS: The disease begins with an initial relapsing-remitting course, followed by progression at a variable rate that may also include occasional relapses and minor remissions.
    - Progressive-relapsing MS: Persons with progressive-relapsing MS experience progressive disease from onset, with clear, acute relapses that may or may not resolve with full recovery. Unlike relapsing-remitting MS, the periods between relapses are characterized by continuing disease progression.
    - Primary progressive MS: The disease shows gradual progression of disability from its onset, without plateaus or remissions or with occasional plateaus and temporary minor improvements.
- MG:
  - MG is a disorder of neuromuscular function that is characterized by fatigue and weakness of the muscular system without atrophy or sensory deficits.
  - Myasthenia “Crisis” refers to exacerbation sufficient to endanger life, and usually involves respiratory failure in MG, therefore would not include disabled patients who are able to walk with or without assistance.
  - IVIG has not been shown to be superior to plasmapheresis in the treatment of life-threatening myasthenia gravis.
  - High-dose IVIG may temporarily modify the immune system and suppress autoantibody production to improve severe myasthenia gravis symptoms. The effect of IVIG is seen typically in less than a week, and the benefit can last for three to six weeks. IVIG is used to quickly reverse an exacerbation of myasthenia.
  - According to the European Federation of Neurological Studies (EFNS) guidelines on the use of intravenous immunoglobulin in treatment of neurological diseases, the efficacy of IVIG has been proven acute exacerbations of myasthenia gravis and short-term treatment of severe MG (level A recommendation).
  - A small clinical trial conducted by Wegner and Ahmed showed that long-term IVIG was effective. This trial included six patients who were anti-AchR-Ab-positive. These patients received IVIG at a dosage of 400 mg/kg/day for 5 days then a maintenance therapy of 400 mg/kg for 1 day every 3 to 4 months. After a 2 year follow up, all

patients maintained a good functional status and side effects from IVIG did not increase.

- NAIT:
  - NAIT is caused by maternal alloantibodies directed against fetal (paternally inherited) platelet antigens as a result of feto-maternal transplacental passage of incompatible platelets during pregnancy.
  - HPA-1a is the platelet-specific antigen implicated in most cases of neonatal alloimmune thrombocytopenia.
  - Administering IVIG to the mother during pregnancy is the most successful strategy for increasing the fetal platelet count and has become the recommended standard treatment of known fetal alloimmune thrombocytopenia.
  - Studies have shown that weekly infusions (1 g/kg maternal body weight) beginning at 20 to 24 weeks gestation stabilize or increase the fetal platelet count in fetuses with documented alloimmune thrombocytopenia.
  - In very high-risk pregnancies (intracranial hemorrhage in a previous sibling before 30 weeks gestation), some investigators recommend starting IVIG therapy as early as 12 to 14 weeks gestation.
  - Although the mechanism of action of IVIG in FAIT is not clearly defined, it is postulated that IVIG decreases maternal alloantibodies and may also block transplacental transport of maternal antiplatelet antibodies.
  - There is still no consensus on the optimal protocol for managing IVIG after it is begun.
- Paraneoplastic Syndromes
  - Paraneoplastic syndromes are the remote effects of a cancer unrelated to the effects of the tumor or its metastasis. Sometimes they are associated with low immune globulin values and sometimes they are associated with autoantibodies.
  - The combination of IVIG, cyclophosphamide, and methylprednisolone in patients with paraneoplastic cerebellar degeneration and antineuronal antibodies is not effective.
  - Anti-NMDA encephalitis
    - Although no standard of care for anti-NMDA encephalitis exists, on the basis of data from the reviews completed, concurrent IVIG (0.4 g/kg per day for 5 days) and methylprednisolone (1 g/day for 5 days) is preferred over plasma exchange.
    - If no response is seen after 10 days, a second-line therapy is started.
    - Although there is a paucity of randomized controlled and comparative trials regarding the use of IVIG for this disorder, because of the severity of anti-NMDA encephalitis and on the basis of data from the completed reviews and case series, it has been noted that individuals who received early tumor treatment (usually with immunotherapy) had better outcome and fewer neurological relapses than the rest of the patients.
    - IVIG given concurrently with corticosteroids has been determined to assist with full or substantial recovery in approximately 75% of the individuals with anti-NMDA encephalitis.
  - OMS or “dancing eyes-dancing feet” syndrome is a rare neurological disorder that affects infants and young children and has been described in adult patients with cancer.
    - The current therapeutic strategies for OMS provide a broad spectrum of nonselective immunotherapies, including noncytotoxic and cytotoxic drugs,

- intravenous immunoglobulins, adrenocorticotrophic hormone (ACTH) and plasma exchange.
  - Intravenous immunoglobulin G is occasionally used as an alternative to ACTH.
  - Altogether, the available evidence suggests that IVIG may be an effective treatment in parainfectious and idiopathic OMS.
  - Treatment with IVIG has been reported in a few idiopathic adult-onset OMS cases in literature and they have concluded that idiopathic OMS presents an age dependent prognosis and immunotherapy. IVIG seems to be associated with a faster recovery.
  - Trends in the standard of care of OMS report that ACTH, prednisone, and intravenous immunoglobulin were used with equal frequency, but ACTH was associated with the best early response.
- Parvovirus B19 Infection
  - Human parvovirus B19 infection can give rise to the loss of mature red blood cells, severe anemia, and the formation of immune complexes.
  - A robust antibody response is necessary for virus clearance and control of the infection.
  - IVIG has been shown to be effective in recurrent infection in augmenting the inadequate humoral immune response. Based on the evidence available, IVIG therapy has become the standard of care if the aplastic crisis becomes prolonged, even though there are no definitive clinical trials demonstrating the efficacy of HPV B19-induced anemia.
  - Use of IVIG for treatment in parvovirus B19 infection is a category 2A NCCN recommendation.
- Pemphigus Vulgaris and related conditions:
  - IVIG therapy for Pemphigus Vulgaris must be used only for short-term therapy and not as a maintenance therapy.
  - For Pemphigus Vulgaris, Pemphigus Foliaceus, Bullous Pemphigoid, Mucous Membrane Pemphigoid (a.k.a. Cicatricial Pemphigoid), Epidermolysis Bullosa Acquisita: the treatment is considered complete when the patient is free of disease after a 16-week interval between the last two infusion cycles.
  - Examples of clinically significant adverse effects to corticosteroids, immunosuppressive agents (e.g., cyclophosphamide, azathioprine, mycophenolate mofetil) are diabetes or fractures from chronic steroid use.
- PI:
  - Common variable immunodeficiency (CVID), the most frequently diagnosed primary immunodeficiency, is characterized by a low serum IgG level antibody deficiency at least 2 SDs below the mean for age, with most patients having concurrent deficiencies of IgA and IgM. Many Patients with CVID have IgG levels below 639 that require IVIG. However, there are rare instances when a patient will have normal IgG levels. The serum immunoglobulin measurement alone does not establish a diagnosis of CVID. A definitive diagnosis of CVID is established when a patient does not demonstrate a prolonged antibody response to immunization with protein antigens (e.g., tetanus) or carbohydrate antigens (e.g., pneumococcal capsular polysaccharides such as pneumovax).
  - Subclass deficiency or IgG subclass deficiency (IGGSD) is diagnosed in patients with recurrent infections, deficiency in one or more IgG subclass levels (less than the 5<sup>th</sup>

- percentile or 2 standard deviations below), and normal total concentrations of IgG, IgM, and IgA.
- Specific antigen deficiency or functional antibody deficiency is diagnosed in patients 2 years and older who present with recurrent respiratory tract infections, normal immunoglobulin and IgG subclass levels, and impaired IgG response to pneumococcal capsular polysaccharide.
  - The gamma globulin band consists of 5 immunoglobulins: about 80% immunoglobulin G (IgG), 15% immunoglobulin A (IgA), 5% immunoglobulin M (IgM), 0.2% immunoglobulin D (IgD), and a trace of immunoglobulin E (IgE).
  - The use of intravenous immune globulin should be reserved for patients with serious defects of antibody function. All immune deficiency conditions require ongoing monitoring of the patient's clinical condition with measurement of pre-infusion (trough) serum IgG levels.
  - For lifelong treatment serum trough IgG levels should be measured before the infusion, and then monitored every 3 months to maintain low normal level (usually 400 – 600 mg/dl).
  - See Appendix E: Reference Ranges for Immune Globulin Levels
  - **Stiff person syndrome**
    - Stiff person syndrome (also known as Moersch-Woltmann syndrome) is a rare progressive neurological disorder characterized by progressive rigidity and stiffness of the axial musculature, associated with painful spasms, primarily in the lower limbs, neck, and trunk.
    - Symptoms are related to autoantibodies directed against glutamic acid decarboxylase in the nervous system called anti-GAD antibodies. This antibody marker, which is an antibody to an enzyme found both in the pancreas and in nerve tissue, is found in high concentrations in classical Stiff-man syndrome.
    - In most cases, improvement in symptoms occurs with combinations of diazepam and baclofen, often in reasonably high dosage. Where all drug treatments fail to give sufficient relief from spasms and pain, treatment is directed against the underlying immunologic condition with drug choices consisting of steroids (either intravenous or orally), plasma exchange or pooled IVIG.
    - Current treatments do not offer or lead to a cure. However, they are able to control symptoms in the majority of patients.
  - Coverage is excluded for the following indications. The use of immune globulins for these indications is considered investigational due to lack of conclusive, evidence-based data with randomized controlled trials. As such, alternative therapies for these indications include:
    - Critical illness myopathy (necrotizing myopathy): corticosteroids (e.g., prednisone, methylprednisolone), immunosuppressive agents (e.g., cyclophosphamide, methotrexate, azathioprine)
    - Idiopathic progressive neuropathy: corticosteroids
    - Iridocyclitis, unspecified: corticosteroids
    - Orbital myositis, bilateral: corticosteroids
    - Other diseases of capillaries [Clarkson disease (systemic capillary leak syndrome)]: corticosteroids

- On February 2018, CSL Behring announced product discontinuation of Carimune NF given the preference among healthcare professionals and patients for newer, more advanced immune globulin options.  
<https://www.fffenterprises.com/assets/downloads/PR-carimune-nf-letter-of-discontinuation.pdf>

*Appendix E: Reference Ranges for Immune Globulin Levels*

- The Mayo Clinic suggests the following reference ranges of immune globulins:

Age	Total IgG	Total IgA	Total IgM
0 to < 5 months	100-334 mg/dL	7-37 mg/dL	26-122 mg/dL
5 to < 9 months	164-588 mg/dL	16-50 mg/dL	32-132 mg/dL
9 to < 15 months	246-904 mg/dL	27-66 mg/dL	40-143 mg/dL
15 to < 24 months	313-1,170 mg/dL	36-79 mg/dL	46-152 mg/dL
2 to < 4 years	295-1,156 mg/dL	27-246 mg/dL	37-184 mg/dL
4 to < 7 years	386-1,470 mg/dL	29-256 mg/dL	37-224 mg/dL
7 to < 10 years	462-1,682 mg/dL	34-274 mg/dL	38-251 mg/dL
10 to < 13 years	503-1,719 mg/dL	42-295 mg/dL	41-255 mg/dL
13 to < 16 years	509-1,580 mg/dL	52-319 mg/dL	45-244 mg/dL
16 to < 18 years	487-1,327 mg/dL	60-337 mg/dL	49-201 mg/dL
≥ 18 years	767-1,590 mg/dL	61-356 mg/dL	37-286 mg/dL

- Some primary immunodeficiency disorders, such as functional antibody deficiency or specific antibody deficiency exhibit normal total IgG concentration but deficiencies in one or more IgG subclasses. The Mayo Clinic suggests the following references ranges:

Age	IgG1	IgG2	IgG3	IgG4
0 to < 5 months	56-215 mg/dL	≤ 82 mg/dL	7.6-82.3 mg/dL	≤ 19.8 mg/dL
5 to < 9 months	102-369 mg/dL	≤ 89 mg/dL	11.9-74.0 mg/dL	≤ 20.8 mg/dL
9 to < 15 months	160-562 mg/dL	24-98 mg/dL	17.3-63.7 mg/dL	≤ 22.0 mg/dL
15 to < 24 months	209-724 mg/dL	35-105 mg/dL	21.9-55.0 mg/dL	≤ 23.0 mg/dL
2 to < 4 years	158-721 mg/dL	39-176 mg/dL	17.0-84.7 mg/dL	0.4-49.1 mg/dL
4 to < 7 years	209-902 mg/dL	44-316 mg/dL	10.8-102.6 mg/dL	0.8-81.9 mg/dL
7 to < 10 years	253-1,019 mg/dL	54-435 mg/dL	8.5-102.6 mg/dL	1.0-108.7 mg/dL
10 to < 13 years	280-1,030 mg/dL	66-502 mg/dL	11.5-105.3 mg/dL	1.0-121.9 mg/dL
13 to < 16 years	289-934 mg/dL	82-516 mg/dL	20.0-103.2 mg/dL	0.7-121.7 mg/dL
16 to < 18 years	283-772 mg/dL	98-486 mg/dL	31.3-97.6 mg/dL	0.3-111.0 mg/dL
≥ 18 years	341-894 mg/dL	171-632 mg/dL	18.4-106.0 mg/dL	2.4-121.0 mg/dL

*Appendix F: Weight-based Dose Calculations*

- Cost-effective dosing of immune globulins is achieved by dosing based on the lesser of either total body weight (TBW; i.e., actual body weight) or ideal body weight (IBW).
  - IBW for males: 50 kg + (2.3 x inches over 5 feet)
  - IBW for females: 45.5 kg + (2.3 x inches over 5 feet)
- For obese members (e.g., BMI is  $\geq 30$  kg/m<sup>2</sup> or TBW is > 20-30% over IBW), adjusted body weight (adjBW) should be used for dose calculations.
  - $\text{AdjBW} = \text{IBW} + [0.4 \times (\text{TBW} - \text{IBW})]$
- Online adult IBW and adjBW calculator: <https://www.mdcalc.com/ideal-body-weight-adjusted-body-weight>
- Online BMI calculator:  
[https://www.nhlbi.nih.gov/health/educational/lose\\_wt/BMI/bmicalc.htm](https://www.nhlbi.nih.gov/health/educational/lose_wt/BMI/bmicalc.htm)

*Appendix G: States with Regulations against Redirections in Cancer*

State	Step Therapy Prohibited?	Notes
FL	Yes	For stage 4 metastatic cancer and associated conditions
GA	Yes	For stage 4 metastatic cancer. Redirection does not refer to review of medical necessity or clinical appropriateness
IA	Yes	For standard of care stage 4 cancer drug use, supported by peer-reviewed, evidence-based literature, and approved by FDA
LA	Yes <sup>‡</sup>	For stage 4 advanced, metastatic cancer or associated conditions. <sup>‡</sup> Exception if clinically equivalent therapy, contains identical active ingredient(s), and proven to have same efficacy
MS	Yes	<i>*Applies to HIM requests only*</i> For advanced metastatic cancer and associated conditions
NV	Yes	Stage 3 and stage 4 cancer patients for a prescription drug to treat the cancer or any symptom thereof of the covered person
OH	Yes	<i>*Applies to Commercial and HIM requests only*</i> For stage 4 metastatic cancer and associated conditions
OK	Yes	<i>*Applies to HIM requests only*</i> For advanced metastatic cancer and associated conditions
PA	Yes	For stage 4 advanced, metastatic cancer
TN	Yes <sup>^</sup>	For stage 4 advanced metastatic cancer, metastatic blood cancer, and associated conditions <sup>^</sup> Exception if step therapy is for AB-rated generic equivalent, interchangeable biological product, or biosimilar product to the equivalent brand drug
TX	Yes	For stage 4 advanced, metastatic cancer and associated conditions

**V. Dosage and Administration**

Refer to full prescribing information for specific dosage instructions. Dosage must be individualized and is highly variable depending on the nature and severity of the disease and on the individual patient response (e.g., serum IgG trough levels). There is no absolute maximum dosage of immune globulin or hyaluronidase.

Drug Name	Indication	Dosing Regimen	Maximum Dose
Alyglo	PI	300 to 800 mg/kg IV every 21 or 28 days  [Use TBW or IBW, whichever is <i>less</i> ; if member is obese, use adjBW – see <i>Appendix F.</i> ]	Not applicable
Asceniv	PI	300 to 800 mg/kg IV every 3 to 4 weeks  [Use TBW or IBW, whichever is <i>less</i> ; if member is obese, use adjBW – see <i>Appendix F.</i> ]	Not applicable
Bivigam	PI	<u>Initial:</u> 300 to 800 mg/kg IV every 3 to 4 weeks  <u>Maintenance:</u> IV: given every 3 to 4 weeks with dose adjusted per serum IgG level and clinical response  [Use TBW or IBW, whichever is <i>less</i> ; if member is obese, use adjBW – see <i>Appendix F.</i> ]	Not applicable
Cutaquig	PI	Previous immune globulin intravenous (IGIV) dose in grams divided by number of weeks between IV doses and multiplied by 1.30. Provided the total weekly dose is maintained, any dosing interval from daily up to weekly can be used.  [Use TBW or IBW, whichever is <i>less</i> ; if member is obese, use adjBW – see <i>Appendix F.</i> ]	Not applicable
Cuvitru	PI	<u>Initial:</u> Previous IGIV/HyQvia dose in grams divided by number of weeks	Not applicable

Drug Name	Indication	Dosing Regimen	Maximum Dose
		between IV doses and multiplied by 1.30. Prorate the weekly dose and give SC at regular intervals QD to every 2 weeks beginning 1 week after last IV or HyQvia dose.  [Use TBW or IBW, whichever is <i>less</i> ; if member is obese, use adjBW – see <i>Appendix F.</i> ]	
Flebogamma 5%	PI	<u>Initial:</u> 300 to 600 mg/kg IV every 3 to 4 weeks  <u>Maintenance:</u> IV: given every 3 to 4 weeks with dose adjusted per serum IgG level and clinical response  [Use TBW or IBW, whichever is <i>less</i> ; if member is obese, use adjBW – see <i>Appendix F.</i> ]	Not applicable
Flebogamma 10%	ITP	1 g/kg IV QD for 2 consecutive days  [Use TBW or IBW, whichever is <i>less</i> ; if member is obese, use adjBW – see <i>Appendix F.</i> ]	Not applicable
	PI	<u>Initial:</u> 300 to 600 mg/kg IV every 3 to 4 weeks  <u>Maintenance:</u> IV: given every 3 to 4 weeks with dose adjusted per serum IgG level and clinical response  [Use TBW or IBW, whichever is <i>less</i> ; if member is obese, use adjBW – see <i>Appendix F.</i> ]	Not applicable

Drug Name	Indication	Dosing Regimen	Maximum Dose
Gamastan, Gamastan S/D	Hepatitis A prophylaxis	<u>Household and institutional case contacts:</u> 0.1 mL/kg IM once  <u>Travel to Hepatitis A-endemic areas:</u> Up to 1 month stay: 0.1 mL/kg IM once Up to 2 months stay: 0.2 mL/kg IM once 2 months or longer stay: 0.2 mL/kg IM every 2 months  [Use TBW or IBW, whichever is <i>less</i> ; if member is obese, use adjBW – see <i>Appendix F.</i> ]	0.1 mL/kg as a single dose or 0.2 mL/kg every 2 months
	Measles postexposure prophylaxis	0.25 mL/kg IM once  [Use TBW or IBW, whichever is <i>less</i> ; if member is obese, use adjBW – see <i>Appendix F.</i> ]	0.25 mL/kg
	Rubella postexposure prophylaxis	0.55 mL/kg IM once  [Use TBW or IBW, whichever is <i>less</i> ; if member is obese, use adjBW – see <i>Appendix F.</i> ]	0.55 mL/kg
	Varicella postexposure prophylaxis	0.6 to 1.2 mL/kg IM once  [Use TBW or IBW, whichever is <i>less</i> ; if member is obese, use adjBW – see <i>Appendix F.</i> ]	1.2 mL/kg
Gammagard Liquid	MMN	0.5 to 2.4 g/kg/month IV  [Use TBW or IBW, whichever is <i>less</i> ; if member is obese, use adjBW – see <i>Appendix F.</i> ]	Not applicable
	PI	<u>Initial:</u> IV: 300 to 600 mg/kg every 3 to 4 weeks	Not applicable

Drug Name	Indication	Dosing Regimen	Maximum Dose
		<p>SC: Previous IGIV dose in grams divided by number of weeks between IV doses and multiplied by 1.37</p> <p><u>Maintenance:</u> IV: given every 3 to 4 weeks with dose adjusted per serum IgG level and clinical response</p> <p>SC: given once weekly with dose adjusted per PI</p> <p>[Use TBW or IBW, whichever is <i>less</i>; if member is obese, use adjBW – see <i>Appendix F.</i>]</p>	
	CIDP	<p><u>Loading dose:</u> 2 g/kg IV given in divided doses over 2 to 5 consecutive days</p> <p><u>Maintenance dose:</u> 1 g/kg IV given in divided doses over 1 to 4 consecutive days, every 3 weeks</p> <p>[Use TBW or IBW, whichever is <i>less</i>; if member is obese, use adjBW – see <i>Appendix F.</i>]</p>	Not applicable
Gammagard Liquid ERC	PI	<p><u>Initial:</u> IV: 300 to 600 mg/kg every 3 to 4 weeks</p> <p>SC: Previous IGIV dose in grams divided by number of weeks between IV doses and multiplied by 1.37</p> <p><u>Maintenance:</u> IV: given every 3 to 4 weeks with dose adjusted per serum IgG level and clinical response</p>	Not applicable

Drug Name	Indication	Dosing Regimen	Maximum Dose
		SC: given once weekly with dose adjusted per PI  [Use TBW or IBW, whichever is <i>less</i> ; if member is obese, use adjBW – see <i>Appendix F.</i> ]	
Gammagard S/D	CLL	400 mg/kg IV every 3 to 4 weeks  [Use TBW or IBW, whichever is <i>less</i> ; if member is obese, use adjBW – see <i>Appendix F.</i> ]	Not applicable
	ITP	1 g/kg IV, up to 3 doses on alternate days  [Use TBW or IBW, whichever is <i>less</i> ; if member is obese, use adjBW – see <i>Appendix F.</i> ]	Not applicable
	KS	1 g/kg IV single dose or 400 mg/kg IV QD for four consecutive days  [Use TBW or IBW, whichever is <i>less</i> ; if member is obese, use adjBW – see <i>Appendix F.</i> ]	Not applicable
	PI	<u>Initial:</u> IV: 300 to 600 mg/kg every 3 to 4 weeks  <u>Maintenance:</u> IV: given every 3 to 4 weeks with dose adjusted per serum IgG level and clinical response  [Use TBW or IBW, whichever is <i>less</i> ; if member is obese, use adjBW – see <i>Appendix F.</i> ]	Not applicable
Gammaked	CIDP	<u>Loading dose:</u> 2 g/kg IV given in divided doses over	Not applicable

Drug Name	Indication	Dosing Regimen	Maximum Dose
		2 to 4 consecutive days <u>Maintenance dose:</u> 1 g/kg IV every 3 weeks  [Use TBW or IBW, whichever is <i>less</i> ; if member is obese, use adjBW – see <i>Appendix F.</i> ]	
	ITP	1 g/kg IV QD given on 2 consecutive days or 0.4 g/kg IV QD given on 5 consecutive days  [Use TBW or IBW, whichever is <i>less</i> ; if member is obese, use adjBW – see <i>Appendix F.</i> ]	Not applicable
	PI	<u>Initial:</u> IV: 300 to 600 mg/kg every 3 to 4 weeks  SC: Previous IGIV dose in grams divided by number of weeks between IV doses and multiplied by 1.37  <u>Maintenance:</u> IV: given every 3 to 4 weeks with dose adjusted per serum IgG level and clinical response  SC: given once weekly with dose adjusted per PI  [Use TBW or IBW, whichever is <i>less</i> ; if member is obese, use adjBW – see <i>Appendix F.</i> ]	Not applicable
Gammaplex	ITP	1 g/kg IV QD for 2 consecutive days  [Use TBW or IBW, whichever is <i>less</i> ; if member	Not applicable

Drug Name	Indication	Dosing Regimen	Maximum Dose
		is obese, use adjBW – see <i>Appendix F.</i>	
	PI	<p><u>Initial:</u> 300 to 800 mg/kg IV every 3 to 4 weeks</p> <p><u>Maintenance:</u> IV: given every 3 to 4 weeks with dose adjusted per serum IgG level and clinical response</p> <p>[Use TBW or IBW, whichever is <i>less</i>; if member is obese, use adjBW – see <i>Appendix F.</i>]</p>	Not applicable
Gamunex-C	CIDP	<p><u>Initial:</u> 2 g/kg IV given in divided doses over 2 to 4 consecutive days</p> <p><u>Maintenance:</u> 1 g/kg IV on one day or 0.5 g/kg IV on two consecutive days, every 3 weeks</p> <p>[Use TBW or IBW, whichever is <i>less</i>; if member is obese, use adjBW – see <i>Appendix F.</i>]</p>	Not applicable
	ITP	<p>1 g/kg IV QD on 2 consecutive days, or 0.4 g/kg IV QD given on 5 consecutive days</p> <p>[Use TBW or IBW, whichever is <i>less</i>; if member is obese, use adjBW – see <i>Appendix F.</i>]</p>	Not applicable
	PI	<p><u>Initial:</u> IV: 300 to 600 mg/kg every 3 to 4 weeks</p> <p>SC: Previous IGIV dose in grams divided by number of weeks between IV doses and multiplied by 1.37</p>	Not applicable

Drug Name	Indication	Dosing Regimen	Maximum Dose
		<u>Maintenance:</u> IV: given every 3 to 4 weeks with dose adjusted per serum IgG level and clinical response  SC: given once weekly with dose adjusted per PI  [Use TBW or IBW, whichever is <i>less</i> ; if member is obese, use adjBW – see <i>Appendix F.</i> ]	
Hizentra	CIDP	0.2 to 0.4 g/kg SC per week, administered in 1 or 2 sessions over 1 or 2 consecutive days  [Use TBW or IBW, whichever is <i>less</i> ; if member is obese, use adjBW – see <i>Appendix F.</i> ]	Not applicable
	PI	Initial weekly dose: previous IGIV dose in grams divided by number of weeks between IV doses and multiplied by 1.37. Prorate the weekly dose to give SC at regular intervals QD to every 2 weeks beginning 1 to 2 weeks after last IV or SC dose depending on dosing regimen.  [Use TBW or IBW, whichever is <i>less</i> ; if member is obese, use adjBW – see <i>Appendix F.</i> ]	Not applicable
HyQvia	PI	If IG therapy naïve or switching from IGSC: 300 to 600 mg/kg every 3 to 4 weeks after initial ramp-up (see manufacturer labeling)	Not applicable

Drug Name	Indication	Dosing Regimen	Maximum Dose
		<p>If switching from IGIV therapy: Give SC at same dose and frequency as previous IV therapy after initial ramp-up (see manufacturer labeling)</p> <p>[Use TBW or IBW, whichever is <i>less</i>; if member is obese, use adjBW – see <i>Appendix F.</i>]</p>	
	CIDP	<p>Switching from IGIV therapy: Give SC at same dose and frequency as previous IV therapy after initial ramp-up (see manufacturer labeling)</p> <p>[Use TBW or IBW, whichever is <i>less</i>; if member is obese, use adjBW – see <i>Appendix F.</i>]</p>	Not applicable
Octagam 5%	PI	<p><u>Initial:</u> 300 to 600 mg/kg IV every 3 to 4 weeks</p> <p><u>Maintenance:</u> IV: given every 3 to 4 weeks with dose adjusted per serum IgG level and clinical response</p> <p>[Use TBW or IBW, whichever is <i>less</i>; if member is obese, use adjBW – see <i>Appendix F.</i>]</p>	Not applicable
Octagam 10%	ITP	<p>1 g/kg IV QD for 2 consecutive days</p> <p>[Use TBW or IBW, whichever is <i>less</i>; if member is obese, use adjBW – see <i>Appendix F.</i>]</p>	Not applicable
	DM	<p>2 g/kg divided in equal doses given over 2-5</p>	Not applicable

Drug Name	Indication	Dosing Regimen	Maximum Dose
		consecutive days every 4 weeks  [Use TBW or IBW, whichever is <i>less</i> ; if member is obese, use adjBW – see <i>Appendix F.</i> ]	
Panzyga	PI	300 to 600 mg/kg IV every 3 to 4 weeks  [Use TBW or IBW, whichever is <i>less</i> ; if member is obese, use adjBW – see <i>Appendix F.</i> ]	Not applicable
	ITP	1g/kg IV QD for 2 consecutive days  [Use TBW or IBW, whichever is <i>less</i> ; if member is obese, use adjBW – see <i>Appendix F.</i> ]	Not applicable
	CIDP	<u>Loading dose:</u> 2 g/kg (20 mL/kg), divided into 2 daily doses of 1 g/kg (10 mL/kg) given on 2 consecutive days <u>Maintenance dose:</u> 1-2 g/kg (10-20 mL/kg) every 3 weeks divided in 2 doses given over 2 consecutive days	Not applicable
Privigen	CIDP	<u>Loading dose:</u> 2 g/kg IV in divided doses over 2 to 5 consecutive days <u>Maintenance dose:</u> 1 g/kg IV every 3 weeks  [Use TBW or IBW, whichever is <i>less</i> ; if member is obese, use adjBW – see <i>Appendix F.</i> ]	Not applicable
	ITP	1 g/kg IV QD for 2 consecutive days  [Use TBW or IBW, whichever is <i>less</i> ; if member	Not applicable

Drug Name	Indication	Dosing Regimen	Maximum Dose
		is obese, use adjBW – see <i>Appendix F.</i> ]	
	PI	<p><u>Initial:</u> 200 to 800 mg/kg IV every 3 to 4 weeks</p> <p><u>Maintenance:</u> IV: given every 3 to 4 weeks with dose adjusted per serum IgG level and clinical response</p> <p>[Use TBW or IBW, whichever is <i>less</i>; if member is obese, use adjBW – see <i>Appendix F.</i>]</p>	Not applicable
Qivigy	PI	<p>300 to 800 mg/kg IV every 3 to 4 weeks. Dosage may be adjusted over time to achieve the desired trough levels and clinical response.</p> <p>[Use TBW or IBW, whichever is <i>less</i>; if member is obese, use adjBW – see <i>Appendix F.</i>]</p>	Not applicable
Xembify	PI	<p>Previous IGIV dose in grams divided by number of weeks between IV doses and multiplied by 1.37. Prorate the weekly dose and give SC at regular intervals QD to every week beginning 1 week after last IV dose.</p> <p>Or</p> <p>Previous SC weekly dose administered in regular intervals every week.</p> <p>[Use TBW or IBW, whichever is <i>less</i>; if member is obese, use adjBW – see <i>Appendix F.</i>]</p>	Not applicable
Yimmugo	PI	300 to 800 mg/kg IV every 3 to 4 weeks. Dosage may be adjusted over time to	Not applicable

Drug Name	Indication	Dosing Regimen	Maximum Dose
		achieve the desired trough levels and clinical response.	

## VI. Product Availability

Drug	Availability
<b><i>IV administration – ready to use</i></b>	
Alyglo (10%)	Single-use vials: 5, 10, 20 gram
Asceniv (10%)	Single-use vial: 5 gram
Bivigam (10%)	Single-use vials: 5, 10 gram
Flebogamma DIF (5%)	Single-use vials: 0.5, 2.5, 5, 10, 20 gram
Flebogamma DIF (10%)	Single-use vials: 5, 10, 20 gram
Gammaplex (5%)	Single-use bottles: 5, 10, 20 gram
Gammaplex (10%)	Single-use bottles: 5, 10, 20 gram
Octagam (5%)	Single-use bottles: 1, 2.5, 5, 10, 25 gram
Octagam (10%)	Single-use bottles: 2, 5, 10, 20, 30 gram
Panzyga (10%)	Single-use bottles: 1, 2.5, 5, 10, 20, 30 gram
Privigen (10%)	Single-use vials: 5, 10, 20, 40 gram
Qivigy (10%)	Single-use vials: 5, 10 gram
Yimmugo (10%)	Single-use vials: 5, 10, 20 gram
<b><i>IV administration – freeze dried for reconstitution</i></b>	
Gammagard S/D	5% single-use bottle: 5 gram 10% single-use bottle: 10 gram
<b><i>IV or SC administration – ready to use</i></b>	
Gammagard Liquid (10%)	Single-use bottles: 1, 2.5, 5, 10, 20, 30 gram
Gammagard Liquid ERC (10%)	Single-use vials: 50 mL, 100 mL
Gammaked (10%)	Single-use bottles: 1, 2.5, 5, 10, 20 gram
Gamunex-C (10%)	Single-use vials: 1, 2.5, 5, 10, 20, 40 gram
<b><i>SC administration – ready to use</i></b>	
Cutaquig (16.5%)	Single-use vials: 1 g, 1.65 g, 2 g, 3.3 g, 4 g, 8 g (165 mg/mL)
Cuvitru (20%)	Single-use vials: 1, 2, 4, 8, 10 gram
Hizentra (20%)	Single-use vials: 1, 2, 4, 10 gram Single-use prefilled syringes: 1, 2, 4, 10 gram
HyQvia (10%) IgG and 160 U/mL recombinant human hyaluronidase* *Hyaluronidase increases permeability of the local SC tissue for approximately 24 to 48 hours.	Single-use dual vial sets: 2.5 g/25 mL and 200 U/1.25 mL, 5 g/50 mL and 400 U/2.5 mL, 10 g/100 mL and 800 U/5 mL, 20 g/200 mL and 1,600 U/10 mL, 30 g/300 mL and 2,400 U/15 mL
Xembify (20%)	Single-use vials: 1, 2, 4, 10 gram
<b><i>IM administration – ready to use</i></b>	
GamaSTAN (16.5%)	Single-use vials: 2 mL, 10 mL
GamaSTAN S/D (15-18%)	Single-use vials: 2 mL, 10 mL

## VII. References

1. Alyglo Prescribing Information. Teaneck, NJ: GC Biopharma USA, Inc; December 2023. Available at: <https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=fb97b3ec-29ee-4df1-aa99-c23e57a21228>. Accessed January 10, 2025.
2. Asceniv Prescribing Information. Boca Raton, FL: ADMA Biologics; April 2019. Available at: <https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d74f4360-3b51-496c-96fb-84c3976958d2>. Accessed January 10, 2025.
3. Bivigam (immune globulin intravenous- human 10% injection, solution) Prescribing Information. Boca Raton, FL: ADMA Biologics, Inc.; March 2024. Available at: <https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a2244aa0-a6d0-11df-b385-0002a5d5c51b>. Accessed January 10, 2025.
4. Cutaquig Prescribing Information. Hoboken, NJ: Octapharma USA, Inc; November 2021. Available at: <https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f3de095f-791a-85dc-7a14-ec7790cb13aa>. Accessed January 10, 2025.
5. Cuvitru Prescribing Information. Westlake Village, CA: Baxalta US, Inc.; November 2024. Available at: [https://www.shirecontent.com/PI/PDFS/Cuvitru\\_USA\\_ENG.pdf](https://www.shirecontent.com/PI/PDFS/Cuvitru_USA_ENG.pdf) Accessed January 10, 2025.
6. Flebogamma 10% DIF Prescribing Information. Los Angeles, CA: Grifols Biologicals, Inc.; September 2019. Available at: <https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f9bf6322-75b4-4ccf-9a4b-4724203f5eef>. Accessed January 10, 2025.
7. Flebogamma 5% DIF Prescribing Information. Los Angeles, CA: Grifols Biologicals, Inc.; September 2019. Available at: <https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2cf22c72-64ac-45be-b7c6-d20340730096>. Accessed January 10, 2025.
8. GamaSTAN Prescribing Information. Research Triangle Park, NC: Grifols Therapeutics, Inc.; August 2022. Available at: <https://www.gamastan.com/en/hcp>. Accessed January 09, 2025.
9. GamaSTAN S/D Prescribing Information. Research Triangle Park, NC: Grifols Therapeutics, Inc.; 2013. Available at: <https://www.fda.gov/media/86789/download>. Accessed January 09, 2025.
10. Gammagard Liquid Prescribing Information. Westlake Village, CA: Baxalta US Inc.; September 2024. Available at: [www.shirecontent.com/PI/PDFS/GAMLIQUID\\_USA\\_ENG.pdf](http://www.shirecontent.com/PI/PDFS/GAMLIQUID_USA_ENG.pdf). Accessed January 9, 2025.
11. Gammagard Liquid ERC Prescribing Information. Cambridge, MA: Takeda Pharmaceuticals; June 2025. Available at: <https://content.takeda.com/?contenttype=PI&product=GAM&language=ENG&country=USA&documentnumber=2>. Accessed July 9, 2025.
12. Gammagard S/D Prescribing Information. Westlake Village, CA: Baxalta US Inc.; November 2024. Available at: <https://www.takeda.com/en-us/what-we-do/product-portfolio/>. Accessed January 09, 2025.
13. Gammaked Prescribing Information. Research Triangle Park, NC: Grifols Therapeutics Inc.; January 2020. Available at: <https://www.gammaked.com/>. Accessed January 09, 2025.
14. Gammaplex 5% Prescribing Information. Durham, NC: BPL Inc.; May 2024. Available at: <https://www.gammaplex.com/prescribing-information/>. Accessed January 09, 2025.
15. Gammaplex 10% Prescribing Information. Durham, NC: BPL Inc.; May 2024. Available at: <https://www.gammaplex.com/prescribing-information/>. Accessed January 09, 2025.

16. Gamunex-C Prescribing Information. Research Triangle Park, NC: Grifols Therapeutics, Inc.; January 2020. Available at: <https://www.gamunex-c.com>. Accessed January 09, 2025.
  17. Hizentra Prescribing Information. Kankakee, IL: CSL Behring LLC; April 2023. Available at: <https://www.hizentra.com/hcp/cidp>. Accessed January 09, 2025.
  18. HyQvia Prescribing Information. Westlake Village, CA: Baxalta US Inc.; September 2024. Available at: <http://www.hyqvia.com/>. Accessed January 09, 2025.
  19. Octagam 5% Prescribing Information. Hoboken, NJ: Octapharma USA, Inc.; April 2022. Available at: <https://octagamusa.com/>. Accessed January 09, 2025.
  20. Octagam 10% Prescribing Information. Hoboken, NJ: Octapharma USA, Inc.; March 2022. Available at: <https://octagamusa.com/>. Accessed January 09, 2025.
  21. Panzyga Prescribing Information. Hoboken, NJ: Octapharma; March 2021. Available at: <https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9306c5f7-ddf9-5190-d0c1-31ba9ca2d0e0>. Accessed January 09, 2025.
  22. Privigen Prescribing Information. Kankakee, IL: CSL Behring, LLC; March 2022. Available at: <http://labeling.cslbehring.com/PI/US/Privigen/EN/Privigen-Prescribing-Information.pdf>. Accessed January 09, 2025.
  23. Qivigy Prescribing Information. Fort Lee, NJ: Kedrion Biopharma Inc. October 2025. Available at: <https://www.qivigy.com/download/QIVIGI-PI-US-K00.pdf>. Accessed October 7, 2025.
  24. Xembify Prescribing Information. Research Triangle Park, NC: Grifols Therapeutics LLC; July 2024. Available at: <https://www.xembify.com/>. Accessed January 09, 2025.
  25. Yimmugo Prescribing Information. Dreieich, Germany: Biotest AG; June 2024. Available at: <https://www.fda.gov/media/179364/download?attachment>. Accessed January 9, 2025.
  26. Micromedex<sup>®</sup> Healthcare Series [Internet database]. Greenwood Village, Colo: Thomson Healthcare. Updated periodically. Accessed January 9, 2025.
  27. Clinical Pharmacology [database online]. Tampa, FL: Gold Standard, Inc.; 2019. Available at: <http://www.clinicalpharmacology-ip.com/>.
- B-Cell Chronic Lymphocytic Leukemia Infection Prophylaxis*
28. Hallek M, Cheson BD, Catovsky D, et al. CLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL. *Blood*. 2018; 131(25):2745-2760.
  29. National Comprehensive Cancer Network. Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Version 3.2025. Available at: [https://www.nccn.org/professionals/physician\\_gls/pdf/cll.pdf](https://www.nccn.org/professionals/physician_gls/pdf/cll.pdf). Accessed April 24, 2025.
  30. Raanani P, Gafter-Gvili A, Paul M, et al. Immunoglobulin prophylaxis in chronic lymphocytic leukemia and multiple myeloma: a systematic review and meta-analysis. *Leuk Lymphoma*. 2009; 50:764.
- CAR T-Cell Related Toxicities*
31. National Comprehensive Cancer Network. Management of Immunotherapy-Related Toxicities Version 1.2025. Available at: [https://www.nccn.org/professionals/physician\\_gls/pdf/immunotherapy.pdf](https://www.nccn.org/professionals/physician_gls/pdf/immunotherapy.pdf). Accessed April 24, 2025.
- Dermatomyositis/Polymyositis*
32. Koler RC, Montemarano A. Dermatomyositis. *Am Fam Physician*. 2001 Nov 1;64(9):1565-1573. Available at: <https://www.aafp.org/pubs/afp/issues/2001/1101/p1565.html>. Accessed January 9, 2025.

33. Dalakas MC, Koffman B, Fujii M, Spector S, Sivakumar K, Cupler E. A controlled study of intravenous immunoglobulin combined with prednisone in the treatment of IBM. *Neurology* 2001;56:323-7.
34. Dalakas MC, Sonies B, Dambrosia J, Sekul E, Cupler E, Sivakumar K. Treatment of inclusion-body myositis with IVIG: a double-blind, placebo-controlled study. *Neurology* 1997;48:712-6.
35. Lam CG, Manlhiot C, Pullenayegum EM, Feldman BM. Efficacy of intravenous Ig therapy in juvenile dermatomyositis. *Ann Rheum Dis* 2011 Dec;70(12):2089-94.
36. Marie I, Mouthon L. Therapy of polymyositis and dermatomyositis. *Autoimmun Rev*. 2011 Nov;11(1):6-13.
37. Miyasaka N, Hara M, Koike T, et al. Effects of intravenous immunoglobulin therapy in Japanese patients with polymyositis and dermatomyositis resistant to corticosteroids: a randomized double-blind placebo-controlled trial. *Mod Rheumatol* 2012;22(3):382-93.
38. Ruzhansky K, Brannagan TH. Intravenous immunoglobulin for treatment of neuromuscular disease. *Neurology Clinical Practice*. October 2013;440-445.
39. Waldman R, DeWane ME, Lu J. Dermatomyositis: diagnosis and treatment. *J Am Acad Dermatol*. 2020;82:283-96.
40. Oddis CV, Reed AM, Aggarwal R, et al. Rituximab in the treatment of refractory adult and juvenile dermatomyositis and adult polymyositis: a randomized, placebo-phase trial. *Arthritis Rheum*. 2013 February;65(2):314-24.

*Fetal/Neonatal Alloimmune Thrombocytopenia*

41. Brojer E, Husebekk A, Debska M, et al. Fetal/neonatal alloimmune thrombocytopenia: pathogenesis, diagnostics, and prevention. *Arch Immunol Ther Exp*. 2016;64:279-290.
42. Pacheco LD, Berkowitz RL, Moise KJ Jr, et al. Fetal and neonatal alloimmune thrombocytopenia: a management algorithm based on risk stratification. *Obstet Gynecol*. 2011;118(5):1157-63.
43. Petermann R, Bakchoul T, Curtis BR, et al. Investigations for fetal and neonatal alloimmune thrombocytopenia: communication from the SSC of the ISTH. *Journal of Thrombosis and Haemostasis*. 2018; 16:2526-9.
44. Peterson JA, McFarland JG, Curtis BR, Aster R. Neonatal alloimmune thrombocytopenia: pathogenesis, diagnosis, and management. *British Journal of Haematology*. 2013;161:3-14.

*Inflammatory Demyelinating Polyneuropathy (Acute/Guillain-Barre Syndrome)*

45. El-Bayoumi MA, El-Refaey AM, Abdelkader AM, et al. Comparison of intravenous immunoglobulin and plasma exchange in treatment of mechanically ventilated children with Guillain Barré syndrome: a randomized study. *Crit Care* 2011 Jul 11;15(4):R164.
46. Elovaara I, Apostolski S, van Doorn P, et al. EFNS guidelines for the use of intravenous immunoglobulin in treatment of neurological diseases: EFNS task force on the use of intravenous immunoglobulin in treatment of neurological diseases. *Eur J Neurol*. 2008 Sep;15(9):893-908.
47. Hughes RAC, Wijdicks EFM, Barohn R, et al. Practice parameter: immunotherapy for Guillain-Barre syndrome. Report of the Quality Standards subcommittee of the American Academy of Neurology. *AAN*. 2003;61(6).

*Inflammatory Demyelinating Polyneuropathy (Chronic)*

48. Joint Task Force of the EFNS and the PNS. European Federation of Neurological Societies/Peripheral Nerve Society Guideline on management of chronic inflammatory demyelinating polyradiculoneuropathy: report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society—First Revision. *European Journal*

- of Neurology. 2010;17: 356-363. Available at:  
<https://onlinelibrary.wiley.com/doi/10.1111/j.1468-1331.2009.02930.x>. Accessed January 9, 2025.
49. Sander HW, Latov N. Chronic Inflammatory Demyelinating Polyradiculoneuropathy Neurology. 2003 Apr 1; 60(8 Suppl 3): S8-15. Available at:  
<http://www.cidpusa.org/P/VARIANTA.htm>. Accessed January 9, 2025.
50. McMillan HJ, Kang PB, Royden Jones H, et al. Childhood chronic inflammatory demyelinating polyradiculoneuropathy: Combined analysis of a large cohort and eleven published series. Neuromuscular Disorders. Feb 2013;23(2):103-11.
51. Gadian J, Kirk E, Holliday K, et al. Systematic review of immunoglobulin use in paediatric neurological and neurodevelopmental disorders. Developmental Medicine & Child Neurology. 2017;59:136–44.
52. Rogers AB, Zaidman CM, Connolly AM. Pulse oral corticosteroids in pediatric chronic inflammatory demyelinating polyneuropathy. Muscle & Nerve. Sept 2020;62(6):705-9.
53. Oaklander AL, Lunn MP, Hughes RA, van Schaik IN, Frost C, Chalk CH and Cochrane Neuromuscular group. Treatments for chronic inflammatory demyelinating polyradiculoneuropathy (CIDP): an overview of systemic reviews. Cochrane Database Syst Rev. 2017 Jan; 2017(1): CD010369.
54. Joint Task Force of the EFNS and the PNS. European Federation of Neurological Societies/Peripheral Nerve Society Guideline on management of chronic inflammatory demyelinating polyradiculoneuropathy: report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society—First Revision. European Journal of Neurology. 2010;17: 356-363
55. Van den Bergh PYK, van Doorn PA, Hadden RDM, et al. European Academy of Neurology/Peripheral Nerve Society (EAN/PNS) guideline on diagnosis and treatment of chronic inflammatory demyelinating polyradiculoneuropathy: Report of a joint Task Force-Second revision [published correction appears in Eur J Neurol. 2022 Apr;29(4):12
- Idiopathic Thrombocytopenic Purpura (Acute or Chronic)*
56. George JN, Woolf SH, Raskob GE, et al. Idiopathic thrombocytopenic purpura: a practice guideline developed by explicit methods for the American Society of Hematology. Blood 1996;88(1):3-40.
57. Neunert C, Lim W, Crowther M, et al. The American Society of Hematology 2011 evidence-based practice guideline for immune thrombocytopenia. Blood 2011;117(16):4190-4207.
58. Portielje JEA, Westendorp RGJ, Kluin-Nelemans HC, Brand A. Morbidity and mortality in adults with idiopathic thrombocytopenic purpura. Blood 2001;97(9):2549-2554.
59. Provan D, Stasi R, Newland AC, et al. International consensus report on the investigation and management of primary immune thrombocytopenia. Blood. 2010;115(2):168-86.
60. Rodeghiero F, Stasi R, Gernsheimer T, et al. Standardization of terminology, definitions and outcome criteria in immune thrombocytopenia purpura of adults and children: report from an international working group. Blood 2009;113(11): 2386-2293.
61. Neunert C, Terrell DR, Arnold DM, et al. American Society of Hematology 2019 guidelines for immune thrombocytopenia. Blood Advances 2019;3(23): 2829-2866.
62. Provan D, Arnold DM, Bussel JB, et al. Updated international consensus report on the investigation and management of primary immune thrombocytopenia. Blood advances 2019;3(22):3780-3817.

*Kawasaki Syndrome or Incomplete (Atypical) Kawasaki Disease*

63. McCrindle B, Rowley AH, Newburger JW, et al. Diagnosis, treatment, and long-term management of Kawasaki disease. *Circulation*. 2017;135:e927-e999.
64. Gorelik M, Chung SA, Ardalán K, et al. 2021 American College of Rheumatology/Vasculitis Foundation guideline for the management of Kawasaki disease. *Arthritis & Rheumatology* April 2022;74(4):586-596.
65. Jone P, Tremoulet A, Choueiri N, et al. Update on diagnosis and management of Kawasaki disease: A scientific statement from the American Heart Association. *Circulation* 2024;150(23):e481-e500.

*Kidney Transplant*

66. Habicht A, Bröker V, Blume C, et al. Increase of infectious complications in ABO-incompatible kidney transplant recipients—a single centre experience. *Nephrol Dial Transplant*. 2011 Dec;26(12):4124-31. Epub 2011 May 28.
67. Jordan SC, Toyoda M, Kahwaji J, et al. Clinical aspects of intravenous immunoglobulin use in solid organ transplant recipients. *Am J Transplant*. 2011 Feb;11(2):196-202. Epub 2011 Jan 10.
68. Kidney Disease: Improving Global Outcomes (KDIGO) Transplant Work Group. KDIGO clinical practice guideline for the care of kidney transplant recipients. *American Journal of Transplantation* 2009; 9(Suppl 3):S1-S157.
69. Taal: Brenner and Rector's The Kidney, 9<sup>th</sup> ed. 2011 Saunders, An Imprint of Elsevier. Kidney Transplantation.
70. Vo AA. Use of intravenous immune globulin and rituximab for desensitization of highly HLA-sensitized patients awaiting kidney transplantation. *Transplantation*. May 15, 2010; 89 (9): 1095-102.
71. Jordan SC, Vo AA, Peng A, et al. Intravenous Gammaglobulin (IVIg): A Novel Approach to Improve Transplant Rates and Outcomes in Highly HLA-Sensitized Patients. *American Journal of Transplantation* 2006;6: 459-466.
72. Orange JS, Hossny EM, Weiler CR, et al. Use of intravenous immunoglobulin in human disease: A review of evidence by members of the Primary Immunodeficiency Committee of the American Academy of Allergy, Asthma, and Immunology. *J Allergy Clin Immunol* April 2006; 117(4):S525-S553.

*Multifocal Motor Neuropathy*

73. Azulay JP, Blin O, Pouget J, et al. Intravenous immunoglobulin treatment in patients with motor neuron syndromes associated with anti-GM1 antibodies: a double-blind, placebo-controlled study. *Neurology* 1994;44(3 Pt 1):429-32.
74. Harbo T, Andersen H, Jakobsen J. Long-term therapy with high doses of subcutaneous immunoglobulin in multifocal motor neuropathy. *Neurology* 2010;75(15):1377-80.
75. Lehmann HC, Hartung HP. Plasma exchange and intravenous immunoglobulins: mechanism of action in immune-mediated neuropathies. *J Neuroimmunol* 2011;231(1-2):61-9.
76. Olney RK, Lewis RA, Putnam TD, Campellone JV Jr. Consensus criteria for the diagnosis of multifocal motor neuropathy. *Muscle Nerve* 2003;27:117-121. National Guideline Clearinghouse. European Federation of Neurological Societies/Peripheral Nerve Society Guideline on management of paraproteinemic demyelinating neuropathies. Report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society. *J Peripher Nerv Syst* 2006;11(1):9-19.

*Multiple Myeloma*

77. Blombery P, Prince HM, Worth LJ, et al. Prophylactic intravenous immunoglobulin during autologous haemopoietic stem cell transplantation for multiple myeloma is not associated with reduced infectious complications. *Ann Hematol.* 2011 Oct;90(10):1167-72.
78. Chapel HM, Hargreaves R, et al. Randomized trial of intravenous immunoglobulin as prophylaxis against infection in plateau-phase multiple myeloma. *Lancet.* 1994; 343: 1059-1063.
79. National Comprehensive Cancer Network. Multiple Myeloma Version 2.2025. Available at [https://www.nccn.org/professionals/physician\\_gls/pdf/myeloma.pdf](https://www.nccn.org/professionals/physician_gls/pdf/myeloma.pdf). Accessed April 24, 2025.
80. National Comprehensive Cancer Network. Prevention and Treatment of Cancer-Related Infections Version 3.2024. Available at [https://www.nccn.org/professionals/physician\\_gls/pdf/infections.pdf](https://www.nccn.org/professionals/physician_gls/pdf/infections.pdf). Accessed March 4, 2025.
81. National Comprehensive Cancer Network. Management of Immunotherapy-Related Toxicities Version 1.2025. Available at: [https://www.nccn.org/professionals/physician\\_gls/pdf/immunotherapy.pdf](https://www.nccn.org/professionals/physician_gls/pdf/immunotherapy.pdf) Accessed April 24, 2025.
82. Musto P, Brugiattelli M, Carotenuto M. Prophylaxis against infections with intravenous immunoglobulins in multiple myeloma. *Br J Haematol.* 1995 Apr;89(4):945-6.
83. Blombery P, Prince HM, Worth LJ, et al. Prophylactic intravenous immunoglobulin during autologous haemopoietic stem cell transplantation for multiple myeloma is not associated with reduced infectious complications. *Ann Hematol.* 2011 Oct;90(10):1167-72.
84. Lancman G, Lozada K, Athar N, et al. Efficacy of intravenous immunoglobulin for preventing infections in patients with multiple myeloma. *Clinical Lymphoma Myeloma and Leukemia* 2021; 21(5):e470-e476.

*Multiple Sclerosis*

85. Clerico M, Rivoiro C, Contessa G, et al. The therapy of multiple sclerosis with immune-modulating or immunosuppressive drug: a critical evaluation based upon evidence based parameters and published systematic reviews. *Clin Neurol Neurosurg.* 2008;110(9):878-85.
86. Miller AE, Rhoades RW. Treatment of relapsing-remitting multiple sclerosis: current approaches and unmet needs. *Curr Opin Neurol.* 2012 Feb;25 Suppl:S4-10.
87. Rae-Grant A, Day GS, Ann Marrie R, et al. Practice guideline recommendations summary: disease modifying therapies for adults with multiple sclerosis. Report of the guidance development, dissemination, and implementation subcommittee of the American Academy of Neurology. *Neurology* April 2018;90(17):777-788.

*Myasthenia Gravis (MG) and Lambert Eaton Myasthenic Syndrome (LEMS)*

88. Barth D, Nabavi Nouri M, Ng E, I P, Bril V. Comparison of IVIg and PLEX in patients with myasthenia gravis. *Neurology.* 2011 Jun 7;76(23):2017-23.
89. Gilhus NE, Owe JF, Hoff JM, et al. Myasthenia gravis: a review of available treatment approaches. *Autoimmune Dis.* 2011;2011:847393.
90. Keogh M, Sedehizadeh S, Maddison P. Treatment for Lambert-Eaton myasthenic syndrome. *Cochrane Database Syst Rev.* 2011 Feb 16;(2):CD003279.
91. Kim JY, Park KD, Richman DP. Treatment of myasthenia gravis based on its immunopathogenesis. *J Clin Neurol.* 2011 Dec;7(4):173-83.
92. Lindquist S, Stangel M. Update on treatment options for Lambert–Eaton myasthenic syndrome: focus on use of AP. *Neuropsychiatr Dis Treat* 2011; 7: 341–349.

93. Sanders DB, Wolfe GI, Benatar M, et al. International consensus guidance for management of myasthenia gravis. *Neurology*. 2016;87(4): 419-425.
94. Narayanaswami P, Sanders DB, Wolfe GI, et al. International consensus guidance for management of myasthenia gravis 2020 update. *Neurology*. 2021;96(3):114-22.
95. Bodkin C and Pascuzzi RM. Update in the management of Myasthenia Gravis and Lambert-Eaton myasthenic syndrome. *Neurol Clin* 2021; 39:133-146.
96. Titulaer M, Lang B and Verschuuren J. Lambert-Eaton myasthenic syndrome: from clinical characteristics to therapeutic strategies. *Lancet Neurol* 2011; 10:1098-107
97. Kesner VG, Oh SJ, Dimachkie MM, and Barohn RJ. Lambert-Eaton Myasthenic Syndrome. *Neurol Clin*. 2018 May;36(2):379-394.

*Paraneoplastic Neurologic Syndrome*

98. Rossor T, Yeh A, Khakoo Y, et al. Diagnosis and management of Opsoclonus-myoclonus ataxia syndrome in children. *Neurol Neuroimmunol Neuroinflamm*. 2022 May;9(3):1-17.
99. Abbdoud H, Probasco JC, Irani S, et al. Autoimmune encephalitis: proposed best practice recommendations for diagnosis and acute management. *J Neurol Neurosurg Psychiatr* 2021;92:757-768.
100. Vedeler CA, Antoine JC, Giometto B, et al. Management of paraneoplastic neurological syndromes: report of an EFNS Task Force. *European Journal of Neurology* 2006;13:682-690.

*Parvovirus B19 Infection and Anemia*

101. Crabol Y, Terrier B, Rozenberg F, et al. Intravenous immunoglobulin therapy for pure red cell aplasia related to human parvovirus b19 infection: a retrospective study of 10 patients and review of the literature. *Clin Infect Dis*. 2013;56(7):968-77.
102. Frickhofen N, Abkowitz JL, Safford M, et al. Persistent B19 parvovirus infection in patients infected with human immunodeficiency virus type 1 (HIV-1): a treatable cause of anemia in AIDS. *Ann Intern Med*. 1990;113(12):926-33.
103. Koduri PR. Parvovirus B19-related anemia in HIV-infected patients. *AIDS Patient Care STDS*. 2000;14(1):7-11.
104. Moudgil A, Shidban H, Nast CC, et al. Parvovirus B19 infection-related complications in renal transplant recipients: treatment with intravenous immunoglobulin. *Transplantation*. 1997;64(12):1847-50.

*Pediatric Human Immunodeficiency Virus (HIV) Infection Prophylaxis*

105. Falloon J, Eddy J, Wiener L, Pizzo PA. Human immunodeficiency virus infection in children. *J Pediatr*. 1989 Jan;114(1):1-30.
106. Mofenson LM, Brady MT, Danner SP, et al. Guidelines for the prevention and treatment of opportunistic infections among HIV-exposed and HIV-infected children: recommendations from CDC, the National Institutes of Health, the HIV Medicine Association of the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the American Academy of Pediatrics. *MMWR*. 2009; 55(RR11):1-166.
107. Panel on Opportunistic Infections in HIV-Exposed and HIV-Infected Children. Guidelines for the Prevention and Treatment of Opportunistic Infections in HIV-Exposed and HIV-Infected Children. Department of Health and Human Services. Available <https://clinicalinfo.hiv.gov/en/guidelines/hiv-clinical-guidelines-pediatric-opportunistic-infections/whats-new-guidelines?view=full>. Accessed March 4, 2025.
108. Pastori D, Esposito A, Mezzaroma I. Immunomodulatory effects of intravenous immunoglobulins (IVIg) in HIV-1 disease: a systematic review. *Int Rev Immunol*. 2011 Feb;30(1):44-66.

109. The National Institute of Child Health and Human Development's Intravenous Immunoglobulin Study Group. Intravenous immune globulin for the prevention of bacterial infections in children with symptomatic human immunodeficiency virus infection. *N Engl J Med*. Jul 11, 1991;325(2):73-80.

*Pemphigus Disorders*

110. Ahmed A. IVIG therapy in the treatment of patients with bullous pemphigus unresponsive to conventional immunosuppressive treatment. *J Am Acad. Derm.* 2001;45:1.
111. Bystryn JC, Jiao D, Natow S. Treatment of pemphigus with intravenous immunoglobulin. *J Am Acad Dermatol*. 2002;47(3):358-63.
112. Harman KE, Albert S, Black MM. Guidelines for the management of pemphigus vulgaris. *Br J Dermatol* 2003 Nov;149(5):926-37.
113. Ishii N, Hashimoto T, Zillikens D, et al. High-dose intravenous immunoglobulin (IVIG) therapy in autoimmune skin blistering diseases. *Clin Rev Allergy Immunol* 2010; 38:186.
114. Murrell DF, Pena S, Joly P, et al. Diagnosis and management of pemphigus: recommendations by an international panel of experts. *J Am Acad Dermatol*. 2018 Feb 10;82(3):575-85.
115. Sami N, Qureshi A, Ruocco E, Ahmed AR. Corticosteroid-sparing effect of intravenous immunoglobulin therapy in patients with pemphigus vulgaris. *Arch Dermatol*. 2002;138(9):1158-62.

*Primary Immunodeficiencies*

116. Bonilla FA, Khan DA, Ballas ZK, et al. Practice parameter for the diagnosis and management of primary immunodeficiency. *J Allergy Clin Immunol*. 2015;136(5):1186-1205.e78.
117. Calvelli TA, Rubinstein A. Intravenous gamma-globulin in infant acquired immunodeficiency syndrome. *Pediatr Infect Dis*. 1986 May-Jun;5(3 Suppl):S207-10.
118. Eijkhout HW, van Der Meer JW, Kallenberg CG, et al. The effect of two different dosages of intravenous immunoglobulin on the incidence of recurrent infections in patients with primary hypogammaglobulinemia. A randomized, double-blind, multicenter crossover trial. *Ann Intern Med*. 2001 Aug 7;135(3):165-74.
119. Kohn DB, Hershey MS, Puck JM, et al. Consensus approach for the management of severe combined immune deficiency caused by adenosine deaminase deficiency. *J Allergy Clin Immunol*. 2019;143(3):852. Epub 2018 Sep 5.
120. Stiehm ER. Human intravenous immunoglobulin in primary and secondary antibody deficiencies. *Pediatr Infect Dis J*. 1997 Jul;16(7):696-707.

*Stiff Person Syndrome*

121. Gnanapavan S, Vincent A, Giovannoni G. Surviving stiff-person syndrome: a case report. *J Neurol*. 2011 Oct;258(10):1898-900.
122. Nolan JD and Nicholas JA. Stiff-person syndrome: Treatment consists of immunomodulatory therapies and symptom management. *Practical Neurology*. September 2020: 61-64.
123. Baizabal-Carvallo JF and Jankovic J. Stiff-person syndrome: insights into a complex autoimmune disorder. *J Neurol Neurosurg Psychiatry* 2015;86:840-848.
124. Dalakas MC. Therapies in stiff-person syndrome. *Advances and future prospects based on disease pathology. Neurology: neuroimmunology & neuroinflammation* 2023 May;10(3): 1-13.

*Viral Prophylaxis for Hepatitis A, Measles, Varicella, Rubella Viruses*

125. Chart of contraindications and precautions to commonly used vaccines (childhood and adult vaccines). In: Centers for Disease Control. Available at: <https://www.cdc.gov/vaccines/hcp/imz-best-practices/contraindications-precautions.html>. Last reviewed July 25, 2024; Accessed March 4, 2025.

126. Control and Prevention of Rubella: Evaluation and Management of Suspected Outbreaks, Rubella in pregnant women, and surveillance for congenital rubella syndrome. In: Centers for Disease Control, MMWR Recomm Rep. 2001; 50(RR-12):1-23. Available at: <https://www.cdc.gov/mmwr/preview/mmwrhtml/rr5012a1.htm>. Accessed March 4, 2025.
127. Measles (Rubeola). In: Centers for Disease Control. Available at: <https://www.cdc.gov/measles/hcp/clinical-overview>. Last reviewed July 15, 2024. Accessed March 4, 2025.
128. McLean HQ, Fiebelkorn AP, Temte JL and Wallace GS. Prevention of measles, rubella, congenital rubella syndrome, and mumps, 2013: Summary recommendations of the advisory committee on immunization practices (ACIP). Recommendations and Reports. June 2013;62(RR04):1-34.
129. Viral Hepatitis – Hepatitis A Information. In: Centers for Disease Control. Available at: <https://www.cdc.gov/hepatitis-a/hcp/clinical-overview>. Last reviewed January 11, 2024. Accessed March 3, 2025.
130. Nelson NP, Weng MK, Hofmeister MG et al. Prevention of Hepatitis A virus infection in the United States: recommendations of the advisory committee on immunization practices, 2020. Recommendations and Reports. July 2020;69(5):1-38.

*Multiple Indications*

131. Agarwal S, Cunningham-Rundles C. Assessment and clinical interpretation of reduced IgG values. Annals of Allergy, Asthma, and Immunology Sept 2007 99;3:281-283.
132. Agrawal RV, Murthy S, Sangwan V, Biswas J. Current approach in diagnosis and management of anterior uveitis. Indian J Ophthalmol. 2010;58(1):11–19. Doi:10.4103/0301-4738.58468.
133. Elovaara I, Apostolski S, van Doorn P, et al. EFNS guidelines for the use of intravenous immunoglobulin in treatment of neurological diseases: EFNS task force on the use of intravenous immunoglobulin in treatment of neurological diseases. Eur J Neurol. 2008 Sep;15(9):893-908.
134. Kirch W, Gold R, Hensel M, et al. Assessment of immunoglobulins in a long-term non-interventional study (SIGNS Study). Rationale, design, and methods. Med Klin (Munich). 2010 Sep;105(9):647-51.
135. Kubota T. Orbital myositis. In: Idiopathic Inflammatory Myopathies – Recent Developments. JT Gran, ed. Rijeka, Croatia; InTech Europe; September 2011. Available at: <http://www.intechopen.com/books/idiopathic-inflammatory-myopathies-recent-developments/orbital-myositis>. Accessed February 16, 2024.
136. Liu X, Treister R, Lang M, Oaklander AL. IVIg for apparently autoimmune small-fiber polyneuropathy: first analysis of efficacy and safety. Ther Adv Neurol Disord. 2018;11:1756285617744484.
137. Mayo Clinic immune globulin lab values accessed at: <http://www.mayomedicallaboratories.com/test-catalog/Clinical+and+Interpretive/8156>. Accessed February 16, 2024.
138. Ramanathan S, Langguth D, Hardy TA, et al. Clinical course and treatment of anti-HMGCR antibody-associated necrotizing autoimmune myopathy. Neurol Neuroimmunol Neuroinflamm. 2015;2(3):e96.
139. Patil AK, Prabhakar AT, Sivadasan A, et al. An unusual case of inflammatory necrotizing myopathy and neuropathy with pipestem capillaries. Neurol India. 2015;63(1):72-76.
140. Perez EE, Orange JS, Bonilla F, et al. Update on the use of immunoglobulin in human disease: a review of evidence. J Allergy Clin Immunol. March 2017;139(3):S1-S46.

141. Petiot P, Choumert A, Hamelin L, et al. Necrotizing autoimmune myopathies. Rev Neurol (Paris). 2013;169(8-9):650-655.
  142. Shinder R, Nasser QJ, Brejt S, et al. Idiopathic inflammation of the orbit and contiguous structures. Ophthal Plast Reconstr Surg. 2012;28(4):10.
  143. Szenborn L. The use of immunoglobulins in the treatment of infectious diseases. Pol Merkur Lekarski. 2011 Jun;30(180):441-7.
  144. Xie Z, Chan EC, Long LM, Nelson C, Druey KM. High-dose intravenous immunoglobulin therapy for systemic capillary leak syndrome (Clarkson disease). Am J Med. 2015 Jan;128(1):91-5.
  145. Cervera R, Rodriguez-Pinto I, Legault K and Erkan D. 16<sup>th</sup> International Congress on antiphospholipid antibodies task force report on catastrophic antiphospholipid syndrome. Lupus 2022; 29(12):1594-2020.
  146. Cervera R, Rodriguez-Pinto I, and Espinosa G. Catastrophic antiphospholipid syndrome: task force report summary. Lupus 2014; 23:1283-1285.
- Weight-based Dosing*
147. Grindeland JW, Grindeland CJ, Moen C, et al. Outcomes associated with standardized ideal body weight dosing of intravenous immune globulin in hospitalized patients: a multicenter study. Ann Pharmacother. Mar 2020;54(3):205-12.
  148. Stump SE, Schepers AJ, Jones AR, et al. Comparison of weight-based dosing strategies for intravenous immunoglobulin in patients with hematologic malignancies. Pharmacotherapy. Dec 2017;37(12):1530-6.
  149. Perez EE, Orange JS, Bonilla F, et al. Update on the use of immunoglobulin in human disease: a review of evidence. J Allergy Clin Immunol. 2017;139:S1-46.
  150. Figgins BS, Aitken SL, Whited LK. Optimization of intravenous immune globulin use at a comprehensive cancer center. AJHP. Dec 2019;76(Suppl 4):S102-6.
  151. Fouche A, Oprica C, Sankaranarayanan J, et al. Retrospective evaluation of IVIG use: appropriateness and potential cost savings from body-weight dosing at a Northeastern tertiary hospital in the United States. RRJHCP. Sep 2016;2(3):19-26.
  152. Anderson CR, Olson JA. Correlation of weight-based i.v. immune globulin doses with changes in serum immunoglobulin G levels. Am J Health-Syst Pharm. Feb 2015;72:285-9.

### Coding Implications

Codes referenced in this clinical policy are for informational purposes only. Inclusion or exclusion of any codes does not guarantee coverage. Providers should reference the most up-to-date sources of professional coding guidance prior to the submission of claims for reimbursement of covered services.

HCP Codes	Description
J1459	Injection, immune globulin (Privigen), intravenous, non-lyophilized (e.g., liquid), 500 mg
J1460	Injection, gamma globulin, intramuscular, 1 cc
J1551	Injection, immune globulin (Cutaquig), 100 mg
J1552	Injection, immune globulin (alyglo), 500 mg
J1554	Injection, immune globulin (Asceniv), 500
J1555	Injection, immune globulin (Cuvitru), 100 mg
J1556	Injection, immune globulin (Bivigam), 500 mg

HCPCS Codes	Description
J1557	Injection, immune globulin (Gammaplex), intravenous, non-lyophilized (e.g., liquid), 500 mg
J1558	Injection, immune globulin (Xembify), 100 mg
J1559	Injection, immune globulin (Hizentra), 100 mg
J1560	Injection, gamma globulin, intramuscular, over 10 cc
J1561	Injection, immune globulin (Gamunex-C/Gammaked), intravenous, non-lyophilized (e.g., liquid), 500 mg
J1566	Injection, immune globulin, intravenous, lyophilized (e.g., powder), not otherwise specified, 500 mg
J1568	Injection, immune globulin (Octagam), intravenous, non-lyophilized (e.g., liquid), 500 mg
J1569	Injection, immune globulin (Gammagard liquid), intravenous, non-lyophilized (e.g., liquid), 500 mg
J1572	Injection, immune globulin (Flebogamma/Flebogamma DIF), intravenous, non-lyophilized (e.g., liquid), 500 mg
J1575	Injection, immune globulin/hyaluronidase (Hyqvia), 100 mg immunoglobulin
J1599	Injection, immune globulin, intravenous, nonlyophilized (e.g., liquid), not otherwise specified, 500 mg
J1577	Injection, immune globulin (panzyga), intravenous, non-lyophilized (e.g., liquid), 500 mg
J3590	Unclassified biologics
C9399	Unclassified drugs or biologicals

Reviews, Revisions, and Approvals	Date	P&T Approval Date
For AIDP/GBS/CIDP: separated existing criteria to clearly delineate which apply to AIDP/GBS and which apply to CIDP; added criteria for confirmation of CIDP diagnosis, per 2010 EFNS/PNS guidelines; added requirement for a prior trial of corticosteroid therapy. RT4 update: added newly approved indication for Panzyga for CIDP.	01.21.21	05.21
3Q 2021 annual review: for myasthenia gravis/LEMS, revised requirement for steroid or alternative immunosuppressant to a requirement for both; for multiple myeloma infection prevention, updated IgG level to < 400 mg/dL per NCCN guidelines; clarification of the requirement on reauth requests for calculating dose based on IBW or adjBW – the requirement is only applicable to adults with diagnoses other than primary immunodeficiency or cancer-related infection prophylaxis, and documentation should be provided for any other diagnoses when there is an inability to adjust dosing; for post-exposure varicella prophylaxis, changed VZIG to VariZIG since VZIG is no longer commercially available; updated	06.17.21	08.21

Reviews, Revisions, and Approvals	Date	P&T Approval Date
reference for HIM off-label use to HIM.PA.154 (replaces HIM.PHAR.21); references reviewed and updated.		
RT4 policy update: revised policy to reflect the FDA's recent approval of Octagam 10% for the treatment of dermatomyositis in adults; revised AR "commercial and HIM" to AR (all lines of business) for allowance of bypassing the exclusion of PANDAS in section III per state regulations.	08.24.21	
Revised requirement for trial of corticosteroid before IG to apply only to CIDP, and no longer to GBS/AIDP, and to only apply when the member does not have CIDP with pure motor symptoms.	09.17.21	02.22
Removed leukemia, acute lymphoblastic from section III: diagnoses/indications for which coverage is NOT authorized; revised continued therapy approval duration for HIM from 6 months to allow for 12 months for primary immunodeficiency per IL State law (215 ILCS 5/356z.24 (b)).	04.20.22	05.22
Added HCPCS code for Cutaquig [J1551].	06.30.22	
3Q 2022 annual review: removed "Dermatomyositis, autoimmune blistering" from Section III, since coverage for this indication is included in the criteria for Sections I.B. (dermatomyositis) and I.O. (pemphigus disorders); removed "Systemic vasculitides" and "Wegener's granulomatosis" from Section III, based on 2021 ACR guidelines and 2016 EULAR guidelines providing some support use of IG products for patients with refractory GPA/MPA; per May SDC and prior clinical guidance added requirement for use of Gammunex-C or Gammaked if Gammagard (or health plan-preferred immune globulin product) is unavailable due to shortage; references reviewed and updated.	05.18.22	08.22
Template changes applied to other diagnoses/indications and continued therapy section.	09.30.22	
2Q 2023 annual review: added limitation of use for HyQvia and Privigen; removed HCPCS code C9270; added HCPCS Codes J1460, J1554, J1558, J1560; removed references to Carimune NF due to product discontinuation; references reviewed and updated. RT4: added new dosage form of Hizentra [50 mL/10 gm prefilled syringe] to policy.	04.18.23	05.23
Added HCPCS code [J1577]	05.24.23	
For Section III, added exclusion of APS does not apply to CAPS; for ADA-SCID, removed trial and failure of Adagen due to product discontinuation; for MS/LEMS and stiff person syndrome, clarified dose to be divided over 2 to 5 consecutive days.	06.20.23	
For Oregon, added allowance of bypassing the exclusion of PANDAS in section III per state regulations.	08.30.23	
RT4: added Alyglo to policy.	12.27.23	

Reviews, Revisions, and Approvals	Date	P&T Approval Date
2Q 2024 annual review: removed Rasmussen's syndrome from Section III; references reviewed and updated. RT4: for HyQvia and Gammagard Liquid, added CIDP indication per updated PI.	01.17.24	05.24
RT4: added Yimmugo to policy.	06.18.24	
For DM, added Gammagard bypass for Octagam requests.	09.12.24	
For California, added allowance of bypassing the exclusion of PANDAS in section III per state regulations. HCPCS code [J1552] added.	11.06.24	
2Q 2025 annual review: for DM, revised verbiage from "for DM, request is for Octagam" to "for Octagam requests, member has DM" for clarity; for CIDP, revised diagnostic criteria from "atypical CIDP" to "CIDP variants" aligning with 2021 EAN/PNS CIDP guidelines; applied redirection language to other diagnoses/indications section; for Section III, clarified usage for "maintenance or chronic" treatment of secondary immunodeficiencies induced by biologic therapies; for Arkansas, added reference to state-specific PANS/PANDAS AR.CP.PHAR.103 policy; references reviewed and updated. Adhoc: added Gamunex as an alternative preferred agent per SDC; added off-label SLL infection prophylaxis per NCCN, added criterion for CAR T-Cell related toxicities (off-label) per NCCN; for MM infection prophylaxis, added bypass of recurrent serious bacterial infections if member has received treatment with BCMA-targeted CAR T-cell therapy or bispecific antibody therapy per NCCN; added oncology bypass language to existing redirections with Appendix G; for continued therapy, added criterion for members currently receiving Gammagard or Gamunex, member continues to use Gammagard or Gamunex, unless medical justification supports necessity for immune globulin product switch; Added step therapy bypass for IL HIM per IL HB 5395.	05.15.25	05.25
Added step therapy bypass for IL HIM per IL HB 5395 to criteria with redirections to preferred IVIG agent and removed specification "to formulary agents" where applicable as bypass is now permitted for non-formulary agents; RT4: added new formulation Gammagard liquid ERC.	07.09.25	
For continued therapy, added language "(or health plan-preferred* immune globulin product)" to continue its usage, unless medical justification supports necessity for immune globulin product switch.	09.19.25	
Per SDC request, removed HIM line of business. RT4: added Qivigy to the policy. Updated Appendix G with revised language and exception for Tennessee.	10.07.25	12.25

**Important Reminder**

This clinical policy has been developed by appropriately experienced and licensed health care professionals based on a review and consideration of currently available generally accepted standards of medical practice; peer-reviewed medical literature; government agency/program approval status; evidence-based guidelines and positions of leading national health professional organizations; views of physicians practicing in relevant clinical areas affected by this clinical policy; and other available clinical information. The Health Plan makes no representations and accepts no liability with respect to the content of any external information used or relied upon in developing this clinical policy. This clinical policy is consistent with standards of medical practice current at the time that this clinical policy was approved. “Health Plan” means a health plan that has adopted this clinical policy and that is operated or administered, in whole or in part, by Centene Management Company, LLC, or any of such health plan’s affiliates, as applicable.

The purpose of this clinical policy is to provide a guide to medical necessity, which is a component of the guidelines used to assist in making coverage decisions and administering benefits. It does not constitute a contract or guarantee regarding payment or results. Coverage decisions and the administration of benefits are subject to all terms, conditions, exclusions, and limitations of the coverage documents (e.g., evidence of coverage, certificate of coverage, policy, contract of insurance, etc.), as well as to state and federal requirements and applicable Health Plan-level administrative policies and procedures.

This clinical policy is effective as of the date determined by the Health Plan. The date of posting may not be the effective date of this clinical policy. This clinical policy may be subject to applicable legal and regulatory requirements relating to provider notification. If there is a discrepancy between the effective date of this clinical policy and any applicable legal or regulatory requirement, the requirements of law and regulation shall govern. The Health Plan retains the right to change, amend or withdraw this clinical policy, and additional clinical policies may be developed and adopted as needed, at any time.

This clinical policy does not constitute medical advice, medical treatment, or medical care. It is not intended to dictate to providers how to practice medicine. Providers are expected to exercise professional medical judgment in providing the most appropriate care, and are solely responsible for the medical advice and treatment of members. This clinical policy is not intended to recommend treatment for members. Members should consult with their treating physician in connection with diagnosis and treatment decisions.

Providers referred to in this clinical policy are independent contractors who exercise independent judgment and over whom the Health Plan has no control or right of control. Providers are not agents or employees of the Health Plan.

This clinical policy is the property of the Health Plan. Unauthorized copying, use, and distribution of this clinical policy or any information contained herein are strictly prohibited. Providers, members, and their representatives are bound to the terms and conditions expressed herein through the terms of their contracts. Where no such contract exists, providers, members and their

representatives agree to be bound by such terms and conditions by providing services to members and/or submitting claims for payment for such services.

**Note:**

**For Medicaid members**, when state Medicaid coverage provisions conflict with the coverage provisions in this clinical policy, state Medicaid coverage provisions take precedence. Please refer to the state Medicaid manual for any coverage provisions pertaining to this clinical policy.

©2012 Centene Corporation. All rights reserved. All materials are exclusively owned by Centene Corporation and are protected by United States copyright law and international copyright law. No part of this publication may be reproduced, copied, modified, distributed, displayed, stored in a retrieval system, transmitted in any form or by any means, or otherwise published without the prior written permission of Centene Corporation. You may not alter or remove any trademark, copyright or other notice contained herein. Centene<sup>®</sup> and Centene Corporation<sup>®</sup> are registered trademarks exclusively owned by Centene Corporation.